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SUMMARY 
The aim of this study was to perform homology modeling of the β-alanyl aminopeptidase 
sequence of Pseudomonas aeruginosa, and to use the model obtained in the design, 
synthesis and testing of inhibitors in order to evaluate the cellular role of this enzyme. 
A 3D model of β-alanyl aminopeptidase was derived and evaluated using Maestro (version 
9.3, Schrödinger). Virtual database screening was then conducted in order to discover 
inhibitors which would be predicted to bind to the active site of the enzyme. Twenty-seven 
hit compounds with the highest docking scores were synthesized, purified and the in vitro 
antimicrobial activities for these synthesized agents, against both Gram-negative and Gram-
positive strains were evaluated using both disc diffusion and micro-dilution assays.  
Under disc diffusion assay, N-(2-aminoethyl)benzenesulfonamide trifluoroacetate salt 1a, 
N-(2-aminoethyl)-4-methylbenzenesulfonamide trifluoroacetate salt 1b, N-(2-aminoethyl)-
4-chlorophenylsulfonamide trifluoroacetate 1c, N-(2-aminoethyl)-4-
nitrophenylsulfonamide trifluoroacetate 1d, N-(2-aminoethyl)-2-nitrophenylsulfonamide 
trifluoroacetate 1e, and 3-amino-N-{2-(2-nitrophenylsulfonamido)ethyl}propanamide 
trifluoroacetate 8e showed the greatest anti-pseudomonal activity. 
Based on disc diffusion assay, against Gram positive and Gram negative strains, 3-Amino-
N-{2-(2-nitrophenylsulfonamido)ethyl}propanamide trifluoroacetate 8e had the greatest 
selectivity, followed by N-(2-aminoethyl)-4-chlorophenylsulfonamide trifluoroacetate 1c 
and N-(2-aminoethyl)-4-methylbenzenesulfonamide trifluoroacetate salt 1b.   
xvii 
Additionally, compound N-(2-aminoethyl)-4-nitrophenylsulfonamide trifluoroacetate 1d 
showed the greatest anti-pseudomonal effect, with an MIC of 78.125 µg/ml. This effect was 
not specific as it also had the greatest effect against B. subtilis and P. vulgaris, with an MIC 
of 156.25 µg/ml for both species. 
These sulfonamides (and their β-alanyl derivatives) represent new leads in the search for 
antimicrobial agents for the treatment of P. aeruginosa. Although compounds 8e, 1c, and 
1b have selective effects upon PA01, their anti-pseudomonal activities are not sufficient for 
the development of potent anti-pseudomonal agents, suggesting that β-alanyl 
aminopeptidase has no physiological role in the growth of Pseudomonas aeruginosa. The 
results obtained in this work do, however, support further work to enhance the activity of 
these non-classical sulphonamides, as well as proteomics and protein purification in order 
to isolate and study β-alanyl aminopeptidase crystallographically. 
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CHAPTER ONE 
INTRODUCTION
2 
1. Introduction 
1.1  Antibacterial Resistance  
Since their initial discovery by Fleming in 1928, and their introduction to the clinic in the 
late 1940s, penicillins have been used for treatment of bacterial infections in millions of 
patients, resulting in significant reductions in the mortality and morbidity rates associated 
with these infections,(1,2) e.g. meningitis and pneumonia. In the late 1950s, some 
Staphylococci were found to be resistant to penicillin,(3) and in the following years 
resistance also developed to later classes of antibacterial agents such as the cephalosporins 
and fluoroquinolones.(4,5)  It soon became clear that microorganisms have developed a 
number of different mechanisms for resistance to antibiotics and multi-drug resistant 
(MDR) bacteria or ‘superbugs’ have now spread worldwide, posing a serious threat to 
global public health, Figure 1. 
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  Figure 1 Worldwide emergence of multidrug resistant bacteria (6) 
The extent of antimicrobial resistance varies around the world.(7) Many bacterial species 
exhibit multi-drug resistance, including, MDR Gram positive and negative organisms, 
example of which are given in Table 1. 
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Table 1 Multidrug resistant (MDR) bacteria 
Gram positive Gram negative  
Staphyloccus aureus  Escherichia coli 
Enterococcus faecalis Acinetobacter baumannii 
Streptococcus pyogenes Pseudomonas aeruginosa 
Streptococcus pneumonia Salmonella 
 
1.2 The Impact of MDR Organisms on Public Health and 
Healthcare Economics 
Drug resistant pathogenic bacteria may result in more frequent periods of illness, longer 
hospital stays and increased health care costs. Multi-drug resistance is exceedingly 
common and there is a high prevalence rate. For example, according to a report from the 
European Molecular Biology Organization (EMBO), infections caused by MRSA and 
VRSA result in 5000 deaths annually worldwide,(8) while in the US 800,000 to 4 million 
patients are infected with Salmonella each year, of which 500 cases are fatal.(9) Almost all 
strains responsible for Staphylococcal infections in the US have some resistance to 
penicillin, and many are also resistant to newer classes of antibacterial agents.(10) In the 
US, the annual hospital expenditure associated with treating infections caused by MRSA is 
$3-4 billion.(11) In Australia and New Zealand, Staphylococcus aureus bacteraemia has a 
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20% mortality rate, which is significantly higher than for infections caused by methicillin-
senstitive S. aureus.(12) The prevalence of antimicrobial resistance is increasing 
worldwide; for example, a study conducted in the US showed that Pseudomonas 
aeruginosa resistance to fluoroquinolones, imipenem, and ceftazidime increased by 37, 32 
and 22%, respectively, between 1997 and 2001.(13) Antimicrobial resistance has been 
recognized as a global crisis and this situation may partly be due to the improper use (or 
overuse) of antibiotics, which can lead to the emergence and persistence of MDR 
organisms. Closer control of antibiotic prescriptions is thus required to overcome the 
problems associated with antimicrobial resistance, provide patients with suitable 
antibiotics, and to ensure cost-effective treatment.(14) Antimicrobial Stewardship (AMS) is 
a healthcare intervention program run in many countries which aims to improve antibiotic 
use through the use of a range of resources and expertise. AMS approaches may produce 
different strategies and guidelines for antibiotics uses by using resources from infectious 
diseases physicians, pharmacists, and microbiologists, as well as governance procedures to 
help in the implementation of these guidelines.(15) 
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1.3  Mechanisms of Antibiotic Resistance  
Antimicrobial resistance in bacteria results from one of two main mechanisms: 
 Acquired resistance  bacteria can acquire resistance by acquisition of DNA from 
other bacteria by horizontal gene transfer, which is mediated by conjugation, 
transduction or transformation. 
 Inherent resistance  in which the bacteria have innate resistance to a class of 
antibacterial agents. For example, Pseudomonas aeruginosa has low susceptibility 
to hydrophobic antibiotics as they have difficulty in penetrating its outer 
membrane.(5, 16)  
‘Superbugs’ exhibit resistance to antibacterial agents by a variety of mechanisms 
including: 
 Drug inactivation or modification; for example bacteria can produce β-lactamase      
enzymes, which cleave the essential β-lactam ring of these antibiotics by catalyzing 
its hydrolysis.(17) 
 Mutation of the antibacterial target site, for example, alteration of the drug binding 
site can lead to the decreased binding of the antibacterial agent to its target. For 
example, Walsh (2003) listed 19 clinically used agents which can be inactivated by 
this mechanism. This is the mechanism found in most resistance in Gram-positive 
bacteria to vancomycin.(18) Another example of this mechanism is the alteration of 
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biochemical pathways; this resistance mechanism is utilized by sulfonamide-
resistant bacteria, which can mutate the dihydropteroate synthase (DHPS) gene in 
the folic acid pathway. DHPS is the target of the sulfonamides and the biosynthesis 
of folic acid, a process unique to prokaryotes, is inhibited by sulfonamides.(19)   
 Active efflux of the antibiotic; for example,  Pseudomonas aeruginosa resistance to 
the fluoroquinolones is due to reduced intracellular antibiotic concentrations.  
Walsh has described the multidrug resistance inducing efflux pumps, which 
contribute to resistance to multiple classes of antibacterial agents.(18) 
1.4  Novel antibiotics 
The persistent spread of antibiotic resistant bacteria and the decrease in the number of 
newly approved antibacterial agents means that the discovery of novel antibiotics to 
counteract the bacterial resistance of currently used antibacterial agents is urgent.(20) 
Pharmaceutical companies are losing interest in the antibiotics market because these drugs 
simply are not as profitable as drugs that treat chronic diseases (long-course treatment).  
The golden age of discovery new antibiotics is past and the period between 1983 and 2001 
just 47 novel antibiotics were approved in North America, since 1998 nine new antibiotics 
were approved, only two of them had a new mode of action: linezolid (Pharmacia and 
Pfizer) and daptomycin (Cubist).(21) Newly developed antibiotics and novel antibiotics 
with new targets will be described below. 
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1.4.1  Lipoglycopeptides 
Telavancin a semi-synthetic vancomycin derivative is a recently introduced (2009) 
lipoglycopeptide antibiotic (Vabativ®). It acts by both inhibiting bacterial peptidoglycan 
production and decreasing membrane depolarization.(22) Dalbavancin is another 
lipoglycopeptide under clinical trial with a longer half-life, up to 250 h.(23) 
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Telavancin 
 
 
Dalbavancin 
 
1.4.2  Oxazolidinones  
Linezolid is a new oxazolidinone, which has a structure which is different from previously 
known oxazolidinones. Linezolid’s mode of action involves the inhibition of bacterial 
10 
 
protein synthesis. Other oxazolidinones are Radezolid, which is in phase 2 clinical trials, 
and Tedizolid, which is in phase 3 clinical trials.(24) 
 
Linezolid 
 
1.4.3  Lipopeptides 
One of the more important classes of antibiotics are the lipopeptides. Mx-2401 is a 
lipopeptide that inhibits peptidoglycan synthesis by targeting C55-P, a substrate which plays 
an important role in peptidoglycan biosynthetic pathways, and targeting this substrate thus 
leads to inhibition of the cell wall precursor lipid production.(25)  
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Mx-2401 
 
1.4.4  Signermycin B 
Signermycin B is a new antibiotic which targets histidine kinase (WalK). Histidine kinase 
(WalK) is one of the two essential components — histidine Kinase (WalK) and WalR 
(response regulator) — which are important for Gram positive bacterial growth and cell 
wall metabolism.(26)   
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Signermycin B 
1.4.5  Actinonin 
Bacterial cell division is considered to be a promising target for new antibiotics, and 
Actinonin is an antibacterial agent that can inhibit peptide deformylase (PDF), an enzyme 
which has a key role in bacterial cell division.(27) 
 
Actinonin 
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1.4.6  β-Lactones 
The β-lactones are natural compounds with promise as antibiotics due to their ability to 
inhibit homoserine transacetylase (HTA), an enzyme which is required for the biosynthesis 
of methionine and so is important for bacteria growth, e.g Obafluorin.(28)  
 
 
Obafluorin 
 
1.4.7  Platensimycin 
Platensimycin is a recently discovered antibiotic which targets the enzymes involved in 
fatty acid biosynthesis and so acts on the formation of the cell membrane of Gram-positive 
bacteria. Platensimycin inhibits β-ketoacyl synthases I/II which are essential for the 
production of bacterial cell membrane fatty acids.(29) 
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Platensimycin 
 
As described before there is an urgent need for the discovery of new antibiotics to compete 
with the significant increase in bacterial resistance and Table 2 lists some of the newly 
developed antibacterial agents and their investigational status. The aim of many researchers 
who are working in this area is to find novel compounds that have antibacterial properties 
via new mechanism and target.(20,30)  
Table 2 Novel antibacterial agents (30) 
Drug Target Note 
AFN-1252 Fatty acid production In Clinical trials 
MX-2401 Bacteria cell wall In Clinical trials 
Radezolid Protein synthesis In Clinical trials 
Surotomycin Membrane depolarization In Clinical trials 
BAL30072 Bacterial cell wall In Clinical trials 
TR-701 Protein synthesis In Clinical trials 
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Fidaxomicin RNA polymerase Launched in 2011 
Biapenem Bacterial cell wall Launched in 2002 
Telithromycin Protein synthesis Approved in 2004 
Daptomycin Bacterial cell membrane Launched in 2003 
Linezolid Protein synthesis Launched in 2000 
 
1.5  Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a Gram-negative aerobic bacterium rod measuring 0.5 to 0.8 
μm by 1.5 to 3.0 μm, which is non-spore forming and non-fermentative, and belongs to the 
Pseudomonadaceae family, Figure 2. P. aeruginosa secretes a variety of pigments, 
including the blue-green pyocyanin, fluorescent pyoverdine and red-brown pyorubin. Most 
P. aeruginosa strains are motile, it is widely distributed in the environment, and normally 
found in soil, water, humans and animal samples. This pathogen has simple nutritional 
requirements and can grow in the absence of oxygen and over a wide temperature 
range.(31,32) All these characteristics help contribute to the classification of P. aeruginosa 
as an opportunistic pathogen — it infects damaged tissues and can produce fatal infections 
in immuno-compromised individuals. P. aeruginosa is a nosocomial pathogen that is 
extremely well adapted to hospital conditions and can be found growing on medical 
equipment, such as catheters, often resulting in cross infection in clinics and hospitals.(31) 
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Figure 2 Gram stain of Pseudomonas.(31) 
 
1.5.1  Pathogenesis  
P. aeruginosa is one of the most effective opportunistic nosocomial pathogens and is 
ranked as the second most common cause of hospital acquired infections in the US 
according to National Nosocomial Infection Surveillance System.(33) P. aeruginosa is 
responsible for around 20% of hospital acquired diseases and can lead to infections in both 
immunocompromised and immunocompetent patients. It can infect the respiratory tract, 
urinary tract, burns, wounds, and also the blood stream.(34) 
Heart. P. aeruginosa can cause endocarditis, which is associated with a high mortality rate, 
by establishing itself on the endocardium through direct invasion from the blood-stream. 
Interestingly, there is a relationship between an increase in Pseudomonas aeruginosa 
induced endocarditis and narcotic addiction.(31,35) 
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Urinary tract.  Urinary tract infections (UTI) which are caused by P. aeruginosa are 
usually nosocomial infections associated with urinary tract instruments or surgery during 
hospitalization. The cause of 40% of Pseudomonas bacteraemia is the invasion of P. 
aeruginosa from the urinary system to the blood-stream.(31,36)  
Blood.  Approximately one quarter of all nosocomial Gram negative P. aeruginosa 
infections are due to bacteraemia in immunocompromised individuals.(31) According to 
Vostrugina et al., Staphylococcus aureus and P. aeruginosa are the most common causes of 
bacteraemia in burn patients.(37)  
Respiratory tract.  Respiratory systems are the most likely to be infected by P. 
aeruginosa. Ventilator associated pneumonia (VAP) is a common disease in intensive care 
units, and has high mortality and morbidity rates.(38) It has been found that 60% of 
ventilator associated pneumonia cases are due to Gram negative bacilli and P. aeruginosa. 
VAP leads to increased healthcare costs due to prolonged hospitalization periods.(39) 
Cystic fibrosis (CF). CF is one of the most prevalent genetically acquired diseases 
affecting young Australians; mostly affecting the lungs and the digestive system. P. 
aeruginosa is one of the most common pathogens which cause lung infections and is the 
main cause of morbidity and mortality in CF patients.(40) 
Brain. Pseudomonas aeruginosa can cause meningitis either as a primary infection (with a 
39% fatality rate), or a secondary infection (with a 66% fatality rate).  The pathogen can 
invade the central nervous system (CNS) from either the urinary tract via the blood or the 
paranasal sinus.(31,36) 
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Ear. As P. aeruginosa flourishes in moist conditions, swimmers are especially prone to 
Pseudomonas otitis externa, which is the most common cause of chronic otitis media 
(approximately 70% of cases) and can spread through vascular channels to the 
leptomeninges, and so lead to meningitis.(41) The most serious Pseudomonal infection of 
the ear is Malignant Otitis Externa (MOE) in diabetics and elderly patients(4) and P. 
aeruginosa is the causative agent in most cases.(31,42)  
Eye. P. aeruginosa is the most common Gram-negative bacterium causing bacterial 
keratitis.  Patients can lose the entire eye if infected with this pathogen due to the bacterium 
secreting enzymes such as elastase and alkaline protease.(31) 
Bone. Osteoarthritis and osteomyelitis can be caused by P. aeruginosa and these infections 
are associated with surgery, compound fractures, drug addiction and extension burns. The 
most frequently targeted sites for these infections are the vertebral column, pelvis, and 
sternoclavicular joint.(31,36) 
Gastrointestinal tract. Many types of Pseudomonas infections can occur in the 
gastrointestinal tract of immunosuppressed patients, such as pediatric diarrhea, 
gastroenteritis, and typhlitis.(31) Typhlitis is the major GIT infection caused by P. 
aeruginosa and it may involve the whole colon.(43) It has also been shown that P. 
aeruginosa can cause diarrhea, especially in immunocompromised patients.(44)     
Skin. Although normal dry skin does not support the growth of P. aeruginosa it has been 
found that infections can occur in moist skin. Approximately 25% of individuals with burns 
are more exposed to this bacterium, which can release protease and toxins and may cause 
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serious problems.(31,36) Dermatological infections that can be caused by P. aeruginosa 
include; green nail syndrome, toeweb infection, ecthyma gangrenosum, Pseudomonas 
septicemia, and Pseudomonas pyoderma.(45) 
 
1.5.2  Detection of Pseudomonas aeruginosa 
The Gram stain procedure is initially used to identify P. aeruginosa but there are many 
other methods to detect this pathogen, such as testing its growth in blood agar or eosin–
methylthionine chloride blue agar. It can also be identified by its fruity odour, or 
fluorescent green colonies when the infected area is exposed to UV light.(31)  A new 
technique for identifying P. aeruginosa targets a specific enzyme and indicates the 
presence of P. aeruginosa with either chromogenic or fluorogenic substrates allowing for 
the rapid and accurate detection of the pathogen, Figure 3.(46)  Groundwater et al. reported 
that phenoxazinones can be used as chromogenic substrates in targeting β-alanyl 
aminopeptidase (BAAP).(47)  The β-alanyl aminopeptidase sequence has been found in the 
genome of Pseudomonas Sp. MCI3434, and has unique substrate specificity for β-alanyl 
dipeptide compared to D-alanine.(48) β-Alanyl aminopeptidase is present in the periplasm 
of P. aeruginosa in significant quantities.(49) These chromogenic substrates, e.g. 1, are 
cleaved only by Pseudomonas strains expressing this enzyme, with the generation of a 
purple colour indicating the release of the core chromogen 2, Figure 4. When 7-N-(-
alanylamino)-1-pentylphenoxazinone substrate 1 was employed, it gave a low degree of 
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diffusion in nutrient media and the colonies of P. aeruginosa were easily 
distinguishable,(47) as shown in Figure 3.                 
 
 
                   
Figure 3 Chromogenic effect in P.aeruginosa in the left two dishes (with no colour      
generation) with other strains of Pseudomonas in the right hand dishes (47) 
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Figure 4 Generation of a purple colour by the action of BAAP on a yellow β-
alanylaminophenoxazinone substrate (47) 
 
1.5.3  Treatment of P. aeruginosa infections 
An early start to a suitable antimicrobial treatment improves patient outcomes while, in 
contrast, inadequate therapy is a cause of P. aeruginosa associated mortality in 
hospitals.(50) Antibiotics which have activity against P. aeruginosa are classified below 
according to their mechanism of action; 
1. Antibiotics which interfere with cell wall synthesis; cephalosporins (such as 
ceftazidime, cefepime, cefoperazone, and cefpirome), penicillins (such as 
ureidopenicillins and carboxypenicillins) and carbapenems (such as meropenem, 
imipenem and doripenem).  
2. Antibiotics which inhibit protein synthesis; aminoglycosides (such as gentamicin, 
amikacin, and tobramycin). 
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3. Antibiotics which interfere with nucleic acid synthesis; quinolones (such as 
ciprofloxacin, levofloxacin, and moxifloxacin). 
4. Antibiotics which disrupt bacterial membrane structures; polymyxins (such as 
polymyxin B and colistin).(51) 
P. aeruginosa is resistant to a number of antimicrobial agents, and amikacin, ceftazidime, 
imipenem, and ciprofloxacin are the commonly prescribed antibiotics for Pseudomonas 
infections. 
1.5.4  Multi-drug resistance in P. aeruginosa  
P. aeruginosa is considered to be a superbug, and can develop resistance to antibiotics 
through all of the mechanisms described in section 1.3. It has both intrinsic and acquired 
resistance to a wide range of antimicrobial agents   this superbug can use one or more 
enzymatic or mutational resistance mechanisms against many classes of antibiotic agents, 
making it an economic and public health concern.(52)  The economic concerns arise due to 
the fact that patients who are infected with P. aeruginosa require extended hospital stays to 
control their infection. Public health problems also arise as P. aeruginosa infections may be 
responsible for increases in both the mortality and morbidity rates associated with 
nosocomial-acquired diseases. In Iran, a survey carried out between January and April 2003 
in Ghotbeddin Burn hospital found that most P. aeruginosa strains isolated from burns 
patients had resistance to all anti-Pseudomonal antibiotics, except meropenem and 
imipenem.(53) In a recent study, conducted in Bathinda, in India, the susceptibility of 193 
P. aeruginosa samples to anti-Pseudomonal agents was assessed over the period March 
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2009 to March 2010  60% of the Pseudomonas isolates were found to be resistant to 
cephalosporins, 75% were resistant to cefotaxime, 63% were resistant to ceftriaxone, 79% 
were resistant to gentamicin, and 73% of the isolates were resistant to ciprofloxacin.(54)     
The specific antibiotic resistance mechanisms exhibited by P. aeruginosa include; 
The production of –lactamases 
As mentioned previously –lactamases catalyse the cleavage of the amide bond in the –
lactam ring, leading to the deactivation of these agents. There are over 300 different –
lactamases, which are present in the bacterial periplasmic space. These enzymes represent 
one of the major causes of P. aeruginosa resistance to –lactam antibiotics. The 
chromosomal β–lactamase, AmpC hydrolyses a wide range of –lactam antimicrobial 
agents, such as aztreonam and third generation cephalosporins.(55,56) Another example are 
the extended spectrum –lactamases (ESBL), which hydrolyse even third generation 
cephalosporins, but not carbapenems.(57) 
 
The production of aminoglycoside modifying enzymes (AMEs) 
Aminoglycoside antibiotics act by inhibiting protein synthesis and can disturb the bacterial 
cell membrane. P. aeruginosa produces AMEs in response to treatment with 
aminoglycoside antibiotics. AMEs are divided into three major classes; aminoglycoside 
phosphoryltransferases, aminoglycoside acetyltransferases, and aminoglycoside 
adenylyltransferases; all of which inhibit the binding ability of aminoglycoside agents to 
the ribosomal subunit.(52) An example of an AME which is secreted by P. aeruginosa is 
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aminoglycoside acetyltransferase, AAC (6')-li, which is linked with resistance to 
gentamicin, and tobramycin. Another example is adenine nucleotide translocator, ANT 
(2'')-I, which is associated with P. aeruginosa resistance to gentamicin and tobramycin.(52)       
 
The expression of efflux pumps 
Efflux pumps play a crucial role in P. aeruginosa resistance to many antimicrobials, and 
this is a non-enzymatic route of –lactam resistance in P. aeruginosa. This resistance 
mechanism involves the over-expression of efflux systems which can be the result of 
mutations in regulatory genes. Four over-expressed efflux pumps have been characterized 
in P. aeruginosa; MexA–MexB–OprM, MexC–MexD–OprJ, MexE–MexF–OprN, and 
MexX–MexY–OprM. These efflux systems play a very important role in the multi-drug 
resistance of P. aeruginosa, especially to aminoglycosides, fluoroquinolones, polymyxin B 
and –lactam antibiotics.(55,56) An example of resistance via this mechanism is the 
resistance of P. aeruginosa to tigecycline.(52,58) 
 
Outer-membrane modification 
Antimicrobial agents have to pass through the porin channels in the outer membrane of 
Gram negative bacteria in order to enter the cell and exert their activity. Livermore has 
demonstrated that the low outer membrane permeability of P. aeruginosa to hydrophilic 
compounds is associated with high resistance to –lactams agents such as imipenem.(59) 
According to Pechere and Kohler, many imipenem resistant P. aeruginosa clinical isolates 
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are differentiated by a deficiency in the OprD porins, which promote the uptake of 
carbapenems and basic amino acids.(55)  
 
1.5.5  The Pseudomonas aeruginosa genome 
 
It is clear that P. aeruginosa has developed many different ways to resist the effect of 
antibiotics and can survive in water, animals, plants, and soil, and recent research has 
attempted to identify the source of its adaptability. Stover et al. proposed that the secret lies 
within the genome of P. aeruginosa which, at 6.3 million base pairs, is one of the largest 
and most complicated bacterial genomes. For comparison, the genome of Bacillus subtilis, 
contains 4.2 Mbp, while those of Escherichia coli, (4.6 Mbp) and Mycobacterium 
tuberculosis, (4.4 Mbp) are also considerably smaller. An understanding of the genome  
should hopefully allow for the development of new antibacterial agents which target 
specific proteins, and thus represent new strategies for the treatment of  infections caused 
by P. aeruginosa.(60) 
1.6  Aminopeptidase Enzymes 
Aminopeptidases are widely distributed in both prokaryotic and eukaryotic organisms and, 
catalyze the cleavage of amino acid residues at the N-terminal position of proteins. 
Bacterial aminopeptidases are localized in the cytoplasm, on the membrane, and in 
periplasm and, to date, more than a hundred bacterial aminopeptidases have been detected. 
Aminopeptidases are classified according to their substrate specificity, into broad- or 
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narrow-acting and according to their catalytic mechanism into metallo-, cysteine and serine 
aminopeptidases.(61) Cahan et al. have reported that P. aeruginosa secretes an 
aminopeptidase which belongs to the metalloprotease family.(62) Komeda and Asano 
detected β-alanyl aminopeptidase in Pseudomonas bacteria in 2005,(48) while Fricke and 
Aurch found that at least four different aminopeptidases occur in the periplasm, leucyl 
aminopeptidase, glutamyl aminopeptidase, alanyl aminopeptidase, and prolyl 
aminopeptidase.(49) Fuchs et al. suggested that β-alanyl aminopeptidase from P. 
aeruginosa is a novel class of enzyme, which could be targeted for the preparation of novel 
antibacterials.(63) As the physiological function of β-alanyl aminopeptidase in P. 
aeruginosa is currently unknown this is an area which requires further research.  
 
1.7  Targeting β-alanyl aminopeptidase in P. aeruginosa  
Targeting of any species-specific enzymatic activity of this microorganism could help rapid 
detection of the pathogen and enable an early start of the appropriate treatment.(46) An 
example of a technique for bacterial detection is the distinction of Gram negative from 
Gram positive bacteria by a method which also employs an aminopeptidase: only Gram 
negative bacteria gave yellow stains within 5 minutes when L-alanine-4-nitroanilide-
impregnated filter paper was placed on bacterial colonies.(64) 
Another example of targeting aminopeptidase activity in P. aeruginosa for detection 
purposes was mentioned previously, in which the -alanylaminopeptidase activity of P. 
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aeruginosa was used to generate a purple colour from a light yellow coloured chromogenic 
enzyme substrate.(47) 
In addition to its use in the detection of P. aeruginosa, if -alanyl aminopeptidase is 
essential for the growth of this organism, inhibition could provide a new class of anti- 
pseudomonal agents. 
1.8  Protein Structure Prediction 
Enzymes are large biological molecules responsible for cellular process and play a crucial 
role in many diseases. An understanding of the protein structure which is linked to their 
function is very important for the discovery of new effective treatments for disease.(65) As 
there are often difficulties in obtaining sufficient amounts of pure protein for  high quality 
crystal structure, homology modeling  and protein threading approaches help to predict the 
three dimensional structure of enzymes from their primary amino acid sequence and so help 
in analyzing the structure and it is properties. A subsequent structure based drug design 
approach can significantly save both the cost and time involved in discovering effective 
therapeutic agents, and the three dimensional structure of the target is required for this 
process, in order to understand the function and the interactions with the ligands.(66) 
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1.9  Homology Modeling 
Homology modeling, or comparative modeling, is the process by which computational 
algorithms are used to predict three dimensional structure of a protein starting from its 
primary amino acid sequence. This method is currently the most reliable approach for the 
prediction of protein 3D structure, the principle being based on protein sequence similarity, 
as more similar enzyme sequences will have more similar structures and functions.(67,68) 
In this approach, the enzyme sequence with an unknown 3D structure (Target) is aligned 
with one or more protein sequences with a known 3D structure (Template). The accuracy of 
the homology modeling approach is dependent upon the similarity between the target and 
template sequences being greater than 30% in order to obtain good alignment.(65) The 
limitations of this technique can arise from the selection of the wrong template, and the 
incorrect alignment of the target and template sequences.(69) 
 
The four main steps in homology modeling are; 
 Identification of one or more known templates with similar primary sequence to the 
target. 
 Alignment of the target and template sequences.   
 Generation of the model(s), and 
 Evaluation of the model(s) generated. 
 
 
29 
 
1.9.1  Identification of template protein 
The first step in homology modeling is to identify one or more proteins with a known three 
dimensional structure to serve as the template. These proteins should have amino acid 
sequence similarity to the target sequence. The sequence selection of the best templates is 
considered to be a crucial factor in obtaining an accurate model, and this is performed by a 
sensitive sequence-based search for the closest template. BLAST (Basic Local Alignment 
Search Tool) is an algorithm for the comparison of the amino acid sequences of different 
proteins. There are different software packages for BLAST, which can be used to identify 
the best template such as; 
 Protein-protein BLAST (BLASTP), which compares the sequence of proteins and   
 Nucleotide-nucleotide BLAST (BLASTN), which compares DNA sequences. 
 
In this work BLASTP matching methods were used, in which a pair-wise comparison of the 
target sequence and a protein with known 3D structure is conducted.  The most suitable 
template is the one which has high sequence similarity with the target, and this protein is 
preferably from the same family as the target.(68,69) 
1.9.2  Sequence Alignment 
As the template selection is based on the initial alignment, this alignment is not sufficient to 
be used for construction of a model and a more reliable alignment is needed to align 
structurally equivalent amino acids and to correlate common structural features such as the 
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secondary structure of the catalytic sites. As the sequence alignment is the arrangement of 
the amino acid sequences of the target and template, this alignment is generally described 
by sequence similarity and sequence identity which are represented as a percentage. The 
template can give an accurate model for the target enzyme if the sequence identity is 
greater than 60%, while if the sequence identity is between 20-35%, the template is 
considered to have low homology and this described as the twilight zone. There are many 
programs for sequence alignment, such as CLUSTAL, FASTA, and BLAST 
alignment.(70,71) and the BLAST alignment was used in this work. 
1.9.3  Model Construction 
Starting from the target template alignment, a 3D model can be generated using different 
methods, modeling by rigid-body assembly, modeling by segment matching and modeling 
by satisfaction of spatial restraints. 
1.9.3.1 Modeling by rigid-body assembly  
Modeling by rigid-body assembly is a widely used technique which is based upon finding 
the similarity between the secondary structures of the template and the target, then 
enforcing the template’s secondary structure features on the correlated parts of the 
target.(72) 
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1.9.3.2 Modeling by segment matching 
In segment matching modeling, the models are generated by using a number of atomic 
positions from the template structures as guiding points, this approach can help to construct 
both side chain and main chain of the protein model by using a database of short regions of 
protein structure, geometry, and energy rules.(73) 
1.9.3.3 Modeling by satisfaction of spatial restraints 
 In modeling by satisfaction of spatial restraints, the spatial restraints are obtained from the 
target-template sequence alignment, and this technique can use many different types of 
information about the target, which can be collected from fluorescence spectroscopy, NMR 
spectra, and other experimental information.(74) Restraint-based modeling is probably the 
most promising technique of all homology modeling techniques.  
1.9.4  Model validation 
Validation is a crucial step that can be conducted at different levels of structure, and it is 
important to evaluate the predicted model to check if there are any potential errors, or if 
there are inaccuracies in generating the protein structure.(68) A model with high sequence 
homology alignment will require less effort in model validation than a modeling with low 
homology.(70) There are a number of evaluation approaches, such as PROCHECK and 
MolProbity, these programs are used in the assessment of stereochemical quality, bond 
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lengths, the conformation of the side chains, angle planes, and the Ramachandran plot of 
the predicted model.(65,75) 
1.9.4.1 Ramachandran Plot  
The Ramachandran plot (or Ramachandran diagram) is a technique which is used to 
validate the generated model by measuring the distribution of the amino acids within the 
Ramachandran area. It is a means of visualizing the backbone dihedral angles, ψ against φ, 
of amino acids in the protein.(76) This tool allows us to check the overall quality of the 
generated protein structure by measuring the distribution of the amino acids within the 
favorable and forbidden regions of the plot.(77) 
1.9.4.2 Root Mean Square Deviation (RMSD) 
The generated model can also be assessed by calculating the backbone root mean square 
deviation RMSD (Å), which measures the distance between two sets of points.  RMSD 
shows the accuracy of the generated model compared to well-known structures and for 
identical 3D structures the RMSD is 0.  
1.9.4.3 Molprobity 
Molprobity is a web service for the assessment of a 3D model of a protein and the 
evaluation of the number of serious clashes (clashscore; ≥0.4Å) per 1000 atoms.(78) 
 
33 
 
1.10  Protein-Ligand Docking 
Docking is a method which predicts the suitable conformations of the ligand when it 
interacts with the target protein. In addition, docking allows prediction of possible ligand 
binding sites and the discovery of novel ligands based on virtual screening.(79) The 
docking steps include; 
 Protein preparation 
 Ligand preparation 
 Grid generation 
 Glide docking 
 Induced fitting    
A detailed description of these steps and the evaluation of docked models will be discussed 
in Chapter Two. 
The main aims of Protein Ligand docking are;(80) 
 The correct prediction of binding affinity of related molecules from a known 
active series, 
 Accurate structure modeling, and, 
 The discovery of new ligands through virtual screening. 
Virtual screening can be conducted using virtual libraries of either compounds that have yet 
to be synthesized, or compounds available for purchase from chemical databases. This 
screening can be performed using the Structure Based Virtual Screening (SBVS) or, the 
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High Throughput Screening (HTS) approach. SBVS is considered to be most successful if 
the target structure has been determined at high resolution.(81)     
1.11  β-Alanyl aminopeptidase and homology modeling 
A knowledge of the three-dimensional structure of -alanyl aminopeptidase is important for 
an understanding the mechanism of this enzyme, as well as for the structure-based design 
of small molecules inhibitors which target it. The process of new drug design is greatly 
benefitted by the 3D structural analysis of target enzymes and their interaction with 
potential ligands, but there is currently no 3D structure for alanyl aminopeptidase 
enzyme.  
In this case homology modeling, as outlined in Figure 5, was required for the generation of 
the 3D structure, based upon the amino acid sequences of -alanyl aminopeptidase, as will 
be described in the next chapter. 
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Figure 5 Steps involved in the homology modeling and virtual screening of β- alanyl 
aminopeptidase 
 
 
Model Construction 
Alignment of target template sequences 
Selection of the most accurate template 
Model assessment 
Model Preparation 
Determination of primary amino acid sequence of the target 
Virtual screening 
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1.12  Aims 
As mentioned previously, an aminopeptidase is an enzyme which catalyzes the cleavage of 
amino acid residues at the N-terminus of a peptide.(61) A number of research groups have  
suggested the presence of -alanyl aminopeptidase in Pseudomonas 
species.(48,49,63,82,83) Groundwater and co-workers targeted the -alanyl aminopeptidase 
of Pseudomonas aeruginosa through the synthesis of chromogenic substrates (-
alanylresorufamines) which are selectively hydrolysed by this enzyme.(47) Lyczaka et al. 
described how P. aeruginosa enzymes contribute to infections caused by this organism but 
the precise role of -alanyl aminopeptidase in P. aeruginosa is still unknown.(84) With no 
published data on the 3D structure of this enzyme, the aims of this research are to perform 
homology modeling of the -alanyl aminopeptidase sequence of P. aeruginosa and to use 
the model generated to design and synthesize inhibitors in order to evaluate its cellular role, 
and perhaps discover new antimicrobial agents with the potential to inhibit the growth of P. 
aeruginosa. 
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1.13  Significance  
3D enzyme structures help to provide a fuller understanding of protein function and aid in 
the discovery of an inhibitor through the use of structure databases.(85) To date, the 3D 
structure of alanyl aminopeptidase is not known.  As P. aeruginosa exhibits multi-drug 
resistance, with few effective marketed antibiotics available and, as there has been a steady 
decrease in the number of approved antimicrobials, there is increased interest in the search 
for new agents for the treatment of P. aeruginosa infections.(20) The generation of a 3D 
model of alanyl aminopeptidase should allow the design and synthesis of inhibitors 
which have potential as novel specific agents for the inhibition of the growth of MDR P. 
aeruginosa. In addition, by testing the effect of inhibitors on P. aeruginosa growth, we 
should gain a greater understanding of the role of alanyl aminopeptidase in P. 
aeruginosa. 
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CHAPTER TWO 
HOMOLOGY MODELING 
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2. Homology Modeling 
In order to construct a 3D model for β-alanyl aminopeptidase, the following steps were 
conducted: 
 The primary amino acid sequence of the target was determined. 
 The best template was selected. 
 The template was aligned with the target enzyme sequence. 
 The target protein structure was modeled, and 
 The model generated was evaluated through the docking of a known ligand. 
Schrodinger Maestro 9.3 software was used in the comparative modeling “Prime” (86) and 
docking studies “Glide” (87) in this project. 
2.1  Determining the target sequence   
β-Alanyl aminopeptidase is an enzyme from Pseudomonas spp. which is specific for the 
cleavage of β-alanyl dipeptides.(47,48,62) The sequence of β-alanyl aminopeptidase was 
determined from the National Center for Biotechnology Information (NCBI) database, and 
is available from GenBank: BAE02664.1 under the title ‘beta-alanine specific 
aminopeptidase [Pseudomonas sp. MCI3434]’ (NCBI). The 366 amino acid sequence of 
the target protein is shown in Figure 6. 
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MRIRELGITIGSGIPGVFNAITDVPGVRVGHHTLNVETGDVSIHSGVTVIEPRAGATHLQPCFAGVHVLN 
GNGDATGLEWIRERGLLTSPIAYTNTHSVGVVRDALVAAEREMGKQHTYWCMPVVLETYDGTLNDIWGQH 
VTAEHVQLALQDARSGPVQEGNVGGGTGMICHEFKGGIGTSSRVLGPEQGGWTVGVLVQANYGVREALRV 
GGYPVGTVLGDVPSPFKSEKKVGVPGMGSIVITIATDAPLLPHQCTRLAQRASVGLARVGGGTEDSSGDI 
FIAFAVGNSNLPAANFGHPGEPTTALKMVNNDYISPLFVAAADAVEEAILNAMLGADDLTGCGNTVLALK 
PERLLAALQQVGWKAP 
 
Figure 6 β-Alanine specific aminopeptidase [Pseudomonas sp. MCI3434] sequence in 
FASTA format 
 
After input of the MCI3434 sequence in FASTA format the next step was to find sequence 
homologs. 
2.2  Identification of a template 
After downloading the primary amino acid sequence for the target, the second and most 
crucial step in homology modeling is the selection of accurate homologs. In order to build 
the most appropriate model, the template with the greatest similarity to the target sequence 
(in terms of both structure and function) must be selected. The target sequence was 
imported into the Prime program workspace (Maestro version 9.3) then the search for a 
template was performed using a BLAST homology search (the default is to use BLAST to 
search the non-redundant PDB database). A list of potential templates was obtained and 
displayed in the homologs table and the highest-scoring template was selected by default, 
as shown in Figure 7. 1B65_A was selected (with 43% sequence identity) as the template: 
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1B65_A corresponds to Chain A of L-aminopeptidase D-Ala-esterase amidase (DmpA). 
from Ochrobactrum anthropi.  
             
 
Figure 7 Blast search for template using Prime (Maestro version 9.3) 
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2.2.1 L-Aminopeptidase D-Ala-esterase / amidase (DmpA) from 
Ochrobactrum anthropi  
DmpA has a sequence identity of 43% with the target sequence, it is a serine 
aminopeptidase enzyme which has a distinctive substrate specificity  it is the only known 
enzyme which can catalyze the removal of either an L- or a D-amino acid from the amino 
terminus of a peptide, and is, therefore, called L-aminopeptidase D-ala-esterase / amidase. 
The physiological role of DmpA has not yet been deduced. The DmpA crystal structure 
(PDB 1B65) was carried out by Bompard-Gilles et al., and shows a homotetrameric protein 
of 375 amino acids; each monomer contains two polypeptides (α chain 1-249; β chain 250-
375) which can be generated by autocatalytic cleavage of the Gly249 -Ser250 bond. The 
catalytic residues for 1B65 are; Y146, N218, S250, S288 and G289 Figure 8. Glu144A is 
close to the active site and it is the only negatively charged amino acid in the substrate 
binding pocket, it is important for the stabilization of the positive charge on the 
substrate.(88) 
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Figure 8 The catalytic mechanism of DmpA (adapted from  ref. 88) 
2.3  Alignment of target and template proteins 
After the selection of a template with a known 3D structure (in this case 1B65 chain A 
[1B65_A]), an automated alignment in Prime was carried out in order to align the target 
and template sequences. There are several ways to produce an alignment for use in building 
a structure: 
 Accept the BLAST / PSI-BLAST alignment generated in the find homologs step. 
 Import an alignment (Prime can also use an alignment produced in another 
alignment program). 
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 Generate or import secondary structure predictions, then use the Align program to 
create a new alignment. 
 Edit any of these alignments manually. 
In this project the generated alignment from the template selection step was used, as the 
conserved amino acids for 1B65_A are well aligned with the target sequence, as shown in 
Figure 9. 
    
Figure 9 Sequence alignment window, the red H represents a residue in a helical 
region, and Blue E represents amino acids with extended regions (beta 
sheets).  (Prime, Maestro version 9.3) 
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A survey of the literature showed that there are only four known β-peptidyl 
aminopeptidases from Proteobacteria, and Geueke et al. have reported their alignment, 
Figure 10.(82,89) 
 
Figure 10 Alignment of the amino acid sequences of four β-peptidyl aminopeptidases: 
BapA from strain 3-2W4, BapA from strainY2, BapA from Pseudomonas 
sp.MCI3434 BAE02664 (the target), and DmpA from O. anthropi (the 
template) Red represents to the residue identical in all four enzymes and 
yellow represents residues identical in three of the four enzymes (ALINE 
program).(89) 
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2.4  Modeling of the target enzyme 
Starting from the appropriate sequence alignment, a 3D structure for the target had to be 
constructed and this building process included; 
1. Coordination of the copying of backbone atoms for aligned area and side chains of 
conserved amino acid. 
2. Building insertion and closing the deletions in the alignment. 
3. Minimization of all atoms not derived directly from the template, and 
4. Prediction of the side chain orientations for non-conserved residues. 
By default, Prime software builds insertions, predicts side chain conformations of non-
conserved amino acids, and closes gaps to generate a model with no physical clashes. Once 
the model building process was finished, the model was displayed in the workspace 
superimposed on the template.  The 3D structure for the target was obtained using Prime 
(Maestro version 9.3) shown in Figure 11.  
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Figure 11 Solid ribbon representation of the homology model generated for β-alanyl 
aminopeptidase in Discovery Studio Visualizer Version 3.(90) 
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2.5  Model validation 
Once the 3D model of β-alanyl aminopeptidase had been constructed, it was necessary to 
assess the accuracy of the model generated, and this was done via a Ramachandran plot, 
Molprobity, and the docking of a known target substrate 1 (a chromogenic -
alanylaminophenoxazinone).(47) 
 
1 
2.5.1  Ramachandran plots 
A Ramachandran plot was used to evaluate the model generated, in which each amino acid 
residue is represented by a point, and the plot indicates the distribution of the amino acids 
in the favourable and unfavourable regions of the model. The Ramachandran plot tool in 
Maestro version 9.3 was used to validate the 3D model of β-alanine aminopeptidase, as 
shown in Figure 12. The number of amino acids residues in unacceptable areas represents 
6.8 % of the total residues, and these are located in areas which are distant from the 
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receptor binding site, while 93.2% of the amino acid residues were found within acceptable 
regions of the model.   
               
Figure 12 Ramachandran plot for β-alanine aminopeptidase from Maestro 9.3. Amino 
acid representations are; Glycine (triangle), Proline (square), other amino 
acids (circle). Residues outside the yellow and red areas are in unfavourable 
regions, as the Red and yellow regions represent the favored and allowed 
regions 
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The amino acids that distributed in unfavorable regions in the model are: Gly 203, Gly 233, 
Gly 85, Gly 26, Gly 212, Gly 341, Gly 343, Gly 161, Gly 177, Gly 46, Gly 39, Gly 156, 
Gly 13, Gln 189, Gln 116, Val 41, Thr 340, Ser 89, and Leu 291, and, of these, the closest 
residue to the active site is Gly 233, with a distance of 6.93 Å  as shown in Figure 13. 
 
Figure 13 Distribution of residues in unacceptable regions of the BAAP model, and the 
distance of closest amino acid (Gly233) in Å, as shown in pink. Maestro V 9.3 
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2.5.2  Molprobity 
The generated model was also assessed using the Molprobity website after uploading the 
3D structure of the target. The Molprobity summary, representing the clash score and the 
structure’s percentile value are shown in Table 3.(91) 
Table 3 Molprobity and clash score results from assessment of the modeled enzyme 
using Molprobity 
Homology Model of β-alanyl aminopeptidase 
Clashscore, all atoms 0 100
th
 percentile*  
Clashscore is the number of serious steric overlaps (> 0.4 Å) per 1000 atoms. 
Poor rotamers 14 5.00 % Goal: < 1 % 
MolProbity score 1.53 94
th
 percentile*  
Cβ deviations > 0.25 Å   2 0.63 % Goal: 0 % 
Bad backbone bonds: 0/2736 0.00 % Goal: 0 % 
 
In the two results columns, the left column gives the raw count, the right column gives the percentage.  
*100
th
 percentile is the best among structures of comparable resolution, 0
th
 percentile is the worst. 
The MolProbity score combines the clashscore and poor rotamer score into a single score. 
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2.5.3  Docking of a known substrate  
The modeled structure of β-alanyl aminopeptidase was prepared for docking with a -
alanylaminophenoxazinone substrate 1, a known chromogenic compound which is 
hydrolyzed (with removal of the β-alanyl residue) only by β-alanyl aminopeptidase from 
Pseudomonas aeruginosa.(47) Docking was conducted using the Glide program in Maestro 
version 9.3. 
2.5.3.1  Protein preparation    
The overall quality of the docking is dependent upon the quality of the enzyme structure, so 
the first step was to prepare the β-alanyl aminopeptidase 3D structure through; ﬁxing the 
structure, deleting unwanted chains and water molecules, and ﬁnally performing the 
optimization of the ﬁxed structure. All of these steps were performed using the Protein 
Preparation wizard in Maestro version 9.3, using the default settings shown in Figure 14. 
The automatic protein preparation tasks allow the conversion of a protein from its raw state 
(that is, missing hydrogen atoms or having a charge state) to a state which is acceptable for 
the Maestro software.(92) 
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Figure 14 Protein Preparation Wizard window in Maestro V.9.3 
2.5.3.2  Preparation of the ligand   
The β-alanylaminophenoxazinone substrate 3D structure was drawn, and then refined in 
LigPrep (Maestro version 9.3) as shown in Figure 15 and Figure 16.(93) 
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Figure 15 The 3D structure of β-alanylaminophenoxazinone, 1  
 
Figure 16 LigPrep window in Maestro 9.3 
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2.5.3.3  Receptor grid generation  
The main role of receptor grid generation is to produce a grid containing the location of the 
potential binding pocket, which can be generated either automatically or by specifying the 
amino acids enclosing a binding site. In this work, the grid was generated by selection of 
the conserved amino acids in the template, as Bompard-Gilles et. al. have reported,  the 
following catalytic residues from the target β-alanyl aminopeptidase were selected; 
Glutamic acid (Glu) 127, Tyrosine (Tyr) 129, Asparagine (Asn) 201, Serine (Ser) 239, 
Serine (Ser) 277, and Glycine (Gly) 278 from.(88)    
2.5.3.4  Induced fit docking  
Induced fit docking provides a highly accurate docking result via the following steps: intial 
docking (Glide), induced fit (Prime), and redocking (Glide). In this project the β-
alanylaminophenoxazinone 1 was docked into the β-alanyl aminopeptidase model using 
induced fit docking methodology in Maestro version 9.3, giving a docking score of -9.6. 
2.5.4  Ligand Receptor interactions 
From Figures 17 and 18, it can be clearly seen that the β-alanylaminophenoxazinone 1 fits 
nicely into the active site forming four hydrogen bond interactions with the amino acid 
residues Glu 127, Tyr 129, Gly 278, and Asn 72 of the model. 
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             A 
                        
           B 
Figure 17 A 2D Ligand interaction diagram. B 3D Diagram of ligand 1 in binding 
pocket of β-alanyl aminopeptidase (Maestro version 9.3) 
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Figure 18 β-Alanyl aminopeptidase model with substrate 1 bound to the proposed    
active site in Maestro V 9.3 
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If we look more closely at the substrate binding pocket, it is clear that all amino acids 
involved in the ligand binding site interaction are conserved in the Template 1B65_A, 
Table 4, especially GLU 127 which is the only acidic amino acid close to the active site 
and which may be responsible for stabilization of the α-amino group of the substrate.(88) 
Table 4 Comparison of the active sites of the target β-alanyl aminopeptidase and 
template 1B65_A 
Proposed catalytic function 1B65_A β-Alanyl aminopeptidase 
Oxyanion Hole 1 Tyr 146 Tyr 129 
Oxyanion Hole 2 Asn 218 Asn 201 
Stabilisation  Glu 144 Glu 127 
Indirect involvement in 
catalytic mechanism  
Ser 250, Ser 288, and Gly 
289 
Ser 239, Ser 277, and Gly 
278 
 
2.6  In Silico screening    
After the homology model of β-alanyl aminopeptidase was constructed and evaluated, in 
silico structure based high throughput virtual screening (HTVS), in Maestro version 9.3, 
was used to predict β-alanyl aminopeptidase inhibitors using over 100,000 molecules 
obtained from the Chembridge database.  
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2.7  Selection of hit compounds  
Virtual screening was performed to obtain the best substrate fit with the target, and the 
results were ranked by docking score, as shown in Table 5. The lead compounds were 
identified according to their docking score and their synthesis will be described in the next 
chapter. 
Table 5 In silico screening results Glide (Maestro version 9.3) 
ID Title Docking score 
1 ZINC09426195 -7.891 
2 ZINC11757529 -7.865 
3 ZINC09095060 -7.735 
4 ZINC02884757 -7.650 
5 ZINC04344119 -7.513 
6 ZINC09426194 -7.368 
7 ZINC19169028 -7.302 
8 ZINC19093808 -7.194 
9 ZINC19765764 -7.093 
10 ZINC02571732 -6.960 
11 ZINC04227458 -6.953 
12 ZINC12304536 -6.922 
13 ZINC19765499 -6.922 
14 ZINC20436111 -6.911 
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As can be seen from Table 6, sulfonamide containing hits have some of the highest 
docking scores and so represent possible leads in the search for β-alanyl aminopeptidase 
inhibitors. If these leads were specific inhibitors of an enzyme expressed only by this 
bacterium, these compounds would represent probes of the function of this enzyme in this 
bacterium and, possibly, potential new, highly specific antibacterial agents for the treatment 
of P. aeruginosa based infections. The next chapters detail the synthesis of these 
compounds and their biological testing. 
Table 6 In silico screening results, showing compounds with highest docking scores 
Compound ID Compound Structure 
Docking 
score 
ZINC09426195 
 
-7.891 
ZINC11757529 
 
-7.865 
ZINC09095060 
 
-7.735 
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ZINC02884757 
 
-7.650 
ZINC09426194 
 
-7.368 
 
 2.8  In silico screening round two 
After the first virtual screening results, the HTVS was conducted to find other classes of 
compounds which could act as leads for the design of specific inhibitors of β-alanyl 
aminopeptidase. This process was performed using the same procedure (Protein preparation 
and Grid receptor generation panel), but with 35,000 compounds from different 
Chembridge database, subsets (0, 0.1). From the best scoring 10 hit compounds identified 
through HTVS result, two compounds Figure 19 were selected for β-alanyl aminopeptidase 
inhibition testing on the basis of visual inspection, cost, ease of synthesis and / or 
commercial availability, Table 7. 
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Table 7 In silico screening results, showing compounds with highest docking scores 
from Chembridge database subsets 0 and 0.1 
Compound ID Compound Structure 
Docking 
score 
ZINC12445668 
 
-8.006 
ZINC32580868 
 
-7.684 
ZINC02485430 
 
-7.613 
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ZINC00978443 
 
-7.583 
ZINC19838419 
 
-7.494 
ZINC14967779 
 
-7.357 
ZINC14967784 
 
-7.311 
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ZINC19113241 
 
-7.303 
ZINC23478413 
 
-7.277 
ZINC02075451 
 
-6.495 
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                 ZINC00978443    ZINC02075451 
 
Figure 19 Compounds obtained from HTVS round 2, for testing against β-alanyl 
aminopeptidase (P. aeruginosa growth inhibitory) activity 
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CHAPTER THREE 
SYNTHESIS 
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3. Synthesis 
As can be seen from the results of the high-throughput virtual screening (HTVS) (Scheme 
1), some of the compounds with the best docking scores are sulfonamides.  Therefore, a 
number of new sulfonamides, and their β-alanyl derivatives were synthesized according to 
their docking scores and the availability of suitable starting materials.    
 
Scheme 1 Compounds with high docking score from HTVS 
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3.1 Results and Discussion  
The sulfonamides 1a-g were synthesized from commercially available benzenesulfonyl 
chlorides 2, by a process involving the initial nucleophilic substitution with a mono-
protected ethylenediamine 3, followed by deprotection of the resulting 
aminoethylsulfonamide 4 using trifluoroacetic acid (TFA)  (Scheme 2, Table 8). 
 
Scheme 2 (i) H2NCH2CH2NHBoc 3, DCM, 
i
Pr2NEt, 24 h, r.t.; (ii) TFA, DCM, 2 h, 0    
°C 
 
 
 
 
69 
 
Table 8 % Yields for synthesis of N-protected 4a-g and deprotected sulfonamides 1       
a-g                                            
 
Coupling of sulfonyl chlorides 2 with the mono-protected primary amine 3 (Scheme 2) can 
be considered to be a general method for the preparation of the sulfonamides 1a-g, via the 
Boc-protected aminoethylsulfonamides 4a-g. The protected intermediates were 
characterized by 
1
H and 
13
C NMR spectroscopy, with the 9 aliphatic protons of the Boc-
protecting group observed at 1.35-1.45 and the protons of the aromatic group at 7.2-8.4. 
The subsequent disappearance of the methyl and quaternary carbons of the Boc group upon 
Derivative  R¹ R² % Yield for synthesis of  
4                                1 
a H H 85 82 
b CH3 H 70 95 
c Cl H 81 90 
d NO2 H 82 83 
e H NO2 79 80 
f NHCOCH3 H 95 96 
g NH2 H *** 35 
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treatment with TFA confirmed the removal of the protecting group, as did the loss of the 
carbamate carbonyl stretch, and the sulfonamides 1 a-g were characterized by IR, 
1
H and 
13
C NMR spectroscopy, and high resolution mass spectrometry (HRMS). X-Ray diffraction 
structures were obtained for two of the sulfonamides, 1a and 1d (Figures 20 and 21). 
Table 9 and Table 10 show bond lengths for the crystal structures of 1a and 1d.   
 
Figure 20 Single crystal X-ray structure of sulfonamide 1a 
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Table 9 Bond lengths for Compound 1a 
Atom ID Bond length 
O(2)-S(1) 1.440 
O(1)-S(1) 1.425 
N(1)-C(7) 1.474 
N(1)-S(1) 1.610 
C(8)-N(2) 1.491 
C(8)-C(7) 1.524 
O(3)-C(10) 1.229 
O(4)-C(10) 1.255 
F(1)-C(9) 1.289 
F(2)-C(9) 1.309 
F(3)-C(9) 1.274 
S(1)-C(4) 1.771 
C(4)-C(3) 1.368 
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C(4)-C(5) 1.381 
C(5)-C(6) 1.387 
C(1)-C(2) 1.369 
C(1)-C(6) 1.371 
C(3)-C(2) 1.399 
C(10)-C(9) 1.527 
 
                     
 
Figure 21 Single crystal X-ray structure of sulfonamide 1d 
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Table 10 Bond lengths for Compound 1d 
Atom ID Bond length 
O(6)-C(10) 1.241 
O(5)-C(10) 1.241 
F(2)-C(9) 1.319 
F(1)-C(9) 1.304 
F(3)-C(9) 1.311 
S(1)-O(3) 1.431 
S(1)-O(4) 1.436 
S(1)-N(2) 1.608 
S(1)-C(4) 1.777 
N(2)-C(7) 1.472 
O(2)-N(1) 1.222 
O(1)-N(1) 1.225 
N(3)-C(8) 1.488 
N(1)-C(1) 1.474 
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C(7)-C(8) 1.518 
C(6)-C(1) 1.380 
C(6)-C(5) 1.390 
C(10)-C(9) 1.549 
C(5)-C(4) 1.391 
C(4)-C(3) 1.394 
C(1)-C(2) 1.385 
C(2)-C(3) 1.388 
 
3.1.1 Synthesis of 4-amino-N-(2-aminoethyl)phenylsulfonamide 
The reduction of the 4-nitro protected sulfonamide 4d was attempted with stannous 
chloride in ethanol, refluxing for 24 hours at 80 °C, as shown in Scheme 3. 
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Scheme 3 (i) SnCl2, EtOH, 24 h, 80 ºC; (ii) TFA, DCM, 2 h, 0 ºC 
 
Unfortunately, the reduction of compound 4d, was not successful, therefore the acetamido 
analogue 5 was prepared according to Scheme 4, then deprotected to give acetamido 
analogue 6, which had an acetyl methyl signal at δH 2.10 and δC 23.3, and which was then 
hydrolysed to produce the desired amino-substituted aminoethylphenylsulfonamide 1g, 
with the expected loss of the acetyl signals. 
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Scheme 4 (i) H2NCH2CH2NHBoc 3, DCM, 
i
Pr2NEt, 24 h, r.t.; (ii) TFA, DCM, 2 h, 0 
ºC; (iii) 2M HCl, reflux, 24 h  
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The structure of compound 6 was confirmed by NMR spectroscopy; the 
1
H NMR spectrum 
showed a singlet peak at δ 2.10 for the acetyl methyl, while the 
13
C NMR spectrum showed 
peaks at δ 23.3 for the CH3 and at δ 168 for CONH. The IR spectrum showed a CONH 
stretch at 1716 cm
-1
. The anilinosulfonamide 1g was characterized by IR, 
1
H and 
13
C NMR 
spectroscopy, and HRMS. 
3.1.2  Coupling of the most active sulfonamides with β-alanine 
Derivatives 8a-g with β-alanine linked to these sulfonamides 1a-g were then prepared, in 
order to increase binding to the enzyme, increase selectivity (as -alanyl aminopeptidase is 
specific to P. aeruginosa) and to enhance prokaryotic cellular uptake of β-alanine coupled 
sulfonamides. The coupling reaction, Scheme 4, involved the use of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) as the coupling agent as its by-product has high 
aqueous solubility, thus making work-up easier.  Once again, deprotection gave the TFA 
salt of the free amine, Scheme 5. The role of EDC can be described as in Scheme 6 
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Scheme 5 Coupling of sulfonamides with β-alanine 
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Scheme 6 EDC coupling mechanism.  
 
The structures of all the β-alanyl substituted aminopropylsulfonamides 8a-g were 
confirmed by NMR, IR, and HRMS. The 
1
H NMR spectra for intermediates 7a-g showed a 
singlet peak at approximately δH 1.30 for the 
t
butyl protons, and  peaks at δ 2.6-3 for the 
four methylene protons (CH2CH2) of the β-alanyl group.  The 
13
C NMR spectra for the 
protected compounds 7a-g showed a singlet at ~ δ 28 for the tbutyl methyls, and at δ 155 
and δ 170 for the amide and carbamate C=O respectively. The IR spectra for these 
componds showed NH, CO and S=O stretches.  The 
1H NMR spectra for the deprotected β-
alanyl substituted sulfonamides 8a-g did not show the singlet peak at δ1.3 for the tbutyl 
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protons, but did show signals for the four protons of CH2CH2 of the β-alanyl group. The 
13
C NMR spectra for the deprotected analogues 8a-g did not show the singlet peak at δ 28 
for the 
t
butyl methyls and only showed one C=O peak (at δ 170). 
3.1.3  Coupling of Ciprofloxacin with β-alanine 
In order to investigate the potential for preparing specific antibacterial prodrugs for P. 
aeruginosa through the synthesis of β-alanylaminopeptidase substrates, β-
alanylciprofloxacin was also synthesized, as shown in Scheme 7. Ciprofloxacin 9 was 
coupled with N-Boc-β-alanine in DMF, in the presence of EDC and HOBt, and the usual 
workup gave the product 10 in 91 % yield. The 
1
H NMR spectrum for the protected 
analogue 10 once again showed a signal at δ 1.30 for the tbutyl protons, and the 13C NMR 
spectrum showed 6 methylene signals, including one at δ 8.6 for the cyclopropyl 
methylenes, and a signal at δ 28.6 for the tbutyl methyls. The electrospray ionization mass 
spectrum showed the MH
+
 ion at m/z 503, corresponding to the molecular formula of 
C25H31O6N4F. Treatment of N-Boc-β-alanylciprofloxacin 10 with trifluoroacetic acid, in 
DCM at 0 ºC for 2 h, gave β-alanylciprofloxacin 11 in 95 % yield. The 1H NMR spectrum 
for β-alanylciprofloxacin trifluoroacetate salt 11 showed two signals, at δ 1.15 and 1.28, for 
the cyclopropyl methylene groups, two signals, at δ 2.69 and 2.99, for the β-alanyl 
methylenes, and another 2 signals for the piperdinyl methylenes, at δ 3.33 and 3.61. The 
deprotection was confirmed by the absence of signals for the N-t-butyloxycarbonyl group 
(Boc) in both the 
1
H and 
13
C NMR spectra, while the IR spectrum showed C=O 
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absorbances at 1782 cm-1. The electrospray ionization mass spectrometry showed the MH
+
 
ion at m/z 403 and HRMS confirmed the molecular formula of C20H23O4N4F. 
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Scheme 7 Synthesis of β-alanyl prodrug of Ciprofloxacin 11 
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3.2 Round two HTVS screening  
Scheme 8 shows the new hit compounds which were obtained from the Chembridge 
screening. Compound 12 was ordered from SPECS and compound 13 was synthesized by 
the Gabriel synthesis, involving the initial reaction of theophylline with N-(3-
bromopropyl)phthalimide, followed by deprotection of the resulting 14 with hydrazine, as 
shown in Scheme 9. 
 
Scheme 8 Chembridge screening hits 
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Scheme 9 Gabriel synthesis of compound 13 
3.3  Experimental section  
3.3.1  Spectroscopic instrumentation 
1
H NMR and 
13
C NMR spectra were obtained on a Varian  400MR spectrometer, with an 
SMS autosampler, which has pulsed field gradients and a PFG 5mm ATB broadband probe 
1
H/
19
F/X. Mass spectra were determined on Thermo Scientific TSQ Quantum Access Max 
LCMS/MS. HRMS were determined on a Bruker 7T Fourier Transform Ion Cyclotron 
Resonance Mass Spectrometer (FTICR) in the Mass Spectrometry Facility at the School of 
Chemistry, University of Sydney. IR spectra were recorded on a SHIMADZU FTIR-8400S 
spectrometer. Melting points were measured on a Stuart melting point apparatus.  
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3.3.2 Preparation of Sulfonamides 
3.3.2.1 Preparation of tert-butyl (2-
phenylsulfonamido)ethylcarbamate 4a 
 
Benzenesulfonyl chloride (0.48 ml, 3.75 mmol) was added to a mixture of N-Boc-
ethylenediamine (0.49 ml, 3.1 mmol) and diisopropylethylamine (0.65ml, 4.7 mmol) in 
DCM (5 ml) and the mixture was stirred for 24 hours at room temperature, under  nitrogen. 
When the reaction was complete (as indicated by TLC), the reaction mixture was diluted 
with DCM (10 ml) and washed with water (2 × 20 ml), then brine (2 × 25 ml). The 
combined organic layers were dried with anhydrous Na2SO4, filtered, and the solvent 
evaporated under reduced pressure to give tert-butyl (2-phenylsulfonamido)ethylcarbamate 
4a, as a white solid (565 mg, 85 %); mp 110-115 °C; IR (nujol) νmax /cm
-1
 3363 (NH), 3286 
(NH), 1725 (C=O), 1687 (CONH), 1456 (Ar-C), 1340 (S=O), 1161(C-N), 750 (Ar-H); 
1
H 
NMR (400MHz, CDCl3): δ (ppm) 1.42 (9H, s, C(CH3)3), 3.05 (2H, q, J = 5.6 Hz, 
NHCH2CH2), 3.23 (2H, q, J = 5.6 Hz,  CH2CH2NH), 4.87 (1H, s, NH), 5.32 (1H, s, NH), 
7.49-7.60 (3H, m, ArH), 7.86 (2H, m, ArH); 
13
C NMR (CDCl3): δ (ppm) 28.3 (3 × CH3), 
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40.2 (CH2), 43.7 (CH2), 76.8 (quat., CMe3), 126.9 (2 × CH), 129.1 (2 × CH), 132.6 (CH), 
139.7 (C-SO2); ESIMS m/z 324 (21 %), 323 (MNa
+
, 100), 267 (14), 201 (9).    
3.3.2.2 Preparation of N-(2-aminoethyl)benzenesulfonamide 
trifluoroacetate salt 1a 
 
tert-Butyl (2-phenylsulfonamido)ethylcarbamate 4a (195 mg, 0.65 mmol) was dissolved in 
DCM (3.5 ml) and TFA (0.5 ml) was added to the solution. The reaction mixture was 
stirred in an ice bath for 2 hours, until all the starting material was consumed, and the 
excess TFA was evaporated to yield N-(2-aminoethyl)benzenesulfonamide trifluoroacetate 
salt 1a, as white crystals (160 mg, 82 %); mp 152-156 °C (Found: MH
+
, 201.0693. Calc. 
for C8H13N2O2S: MH, 201.0692); IR (nujol) νmax/cm
-1 
3163 (NH), 1377 (CH2), 1348 (S=O), 
1089 (C-N), 1456 (Ar-C), 721 (Ar-H); 
1
H NMR (400MHz, d6-DMSO): δ (ppm) 2.83 (2H, t, 
J = 6.4 Hz, NHCH2CH2NH), 2.90 (2H, t, J = 6.4 Hz, NHCH2CH2NH), 7.64 (3H, m, ArH), 
7.79 (2H, m, ArH); 
13
C NMR (d6-DMSO): δ (ppm) 31.1 (CH2), 39.8 (CH2), 117.9 (CF3), 
127.6 (2 × CH), 129.8 (2 × CH), 133.2 (CH), 139.8 (C-SO2), 161.8 (C=O); ESIMS m/z 223 
(MNa
+
, 13 %), 202 (16), 201 (MH
+
, 100), 184, (16). 
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3.3.2.3 Preparation of tert-butyl {2-(4-methylphenyl)-
sulfonamido}ethylcarbamate 4b 
 
N-Boc-ethylenediamine (0.49 ml, 3.12 mmol) was added to a mixture of 4-
methylbenzenesulfonyl chloride (714 mg, 3.75 mmol) and diisopropylethylamine (0.65 ml, 
4.7 mmol) in DCM (5 ml) and the mixture was stirred for 24 hours at room temperature, 
under nitrogen. When the reaction was complete (as indicated by TLC), the reaction 
mixture was diluted with DCM (10 ml) and washed with water (2 × 20 ml), then brine (2 × 
25 ml). The combined organic layers were dried over anhydrous Na2SO4, filtered and 
evaporated under reduced pressure. The residue was purified by column chromatography 
on silica, eluting with ethyl acetate-hexane (0:100 to 50:50), to yield tert-butyl {2-(4-
methylphenyl)sulfonamido}ethylcarbamate 4b, as a white solid (505 mg, 71 %); mp 137-
139 °C; IR (nujol) νmax /cm
-1
 3371 (NH), 3286 (NH), 1695 (CO), 1458 (Ar-C), 1377 (CH2), 
1335 (S=O), 1157 (C-O); 
1
H NMR (400MHz, CDCl3): δ (ppm) 1.42 (9H, s, C(CH3)3), 2.42 
(3H, s, CH3), 3.05 (2H, q, J = 5.8 Hz, NHCH2CH2NH), 3.20 (2H, q, J = 5.8 Hz, 
NHCH2CH2NH), 4.86 (1H, s, NH), 5.10 (1H, s, NH), 7.29 (2H, d, J = 8.4 Hz, ArH), 7.73 
(2H, d, J = 8.4 Hz, ArH); 
13
C NMR (CDCl3): δ (ppm) 21.5 (CH3), 28.3 (3 × CH3), 40.2 
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(CH2), 43.6(CH2), 76.6 (quat., CMe3), 127.7 (2 × CH), 129.7 (2 × CH), 136.8 (quat.), 143.4 
(quat.), 156.5 (C=O); ESIMS m/z 338 (21 %), 337 (MNa
+
, 100), 281 (9), 215 (11).   
3.3.2.4 Preparation of N-(2-aminoethyl)-4-methylphenylsulfonamide 
trifluoroacetate salt 1b 
 
tert-Butyl {2-(4-methylphenyl)sulfonamido}ethylcarbamate 4b (200 mg, 0.64 mmol) was 
dissolved in DCM (3.5 ml) and TFA (0.5 ml) was added to the solution.  The reaction 
mixture was stirred in an ice bath for 2 hours, until the reaction was complete, and the 
excess TFA was allowed to evaporate to yield white crystals of N-(2-aminoethyl)-4-
methylbenzenesulfonamide trifluoroacetate salt 1b (190 mg, 95 %); mp 150-154 °C 
(Found: MH
+
, 215.0849. Calc. for C9H14N2O2S: MH, 215.0848); IR (nujol) ν max/cm
-1
 3198 
(NH), 3177 (NH), 1460 (C=C), 1377 (CH2), 1333 (S=O), 748 (Ar-H); 
1
H NMR (400MHz, 
d6-DMSO): δ (ppm) 2.37 (3H, s, CH3), 2.83 (2H, q, J = 5.2 Hz, NHCH2CH2NH), 2.89 (2H, 
q, J = 5.2 Hz, NHCH2CH2NH), 7.41 (2H, d, J = 8.8 Hz, ArH), 7.68 (2H, d, J = 8.8 Hz, 
ArH); 
13
C NMR (d6-DMSO): δ (ppm) 21.4 (CH3), 39.2 (CH2), 39.8 (CH2), 118.1 (CF3), 
127.8 (2 × CH), 130.1 (2 × CH), 137.8 (quat.), 143.5 (quat.), 161.8 (C=O); ESIMS m/z 237 
(MNa
+
, 19 %), 215 (MH
+
, 100), 198 (14).                                                 
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3.3.2.5 Preparation of tert-butyl {2-(4-chlorophenylsulfonamido)-
ethyl}carbamate 4c 
 
4-Chlorobenzenesulfonyl chloride (553 mg, 2.62 mmol) was added to a mixture of N-Boc-
ethylenediamine (0.35 ml, 2.18 mmol) and diisopropylethylamine (0.55 ml, 3.27 mmol) in 
DCM (5 ml), and the mixture was stirred for 24 hours at room temperature, under nitrogen. 
When the reaction was complete (as indicated by TLC), the reaction mixture was diluted 
with DCM (10 ml) and washed with water (2 × 20 ml), then brine (2 × 25 ml). The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and the solvent 
evaporated under pressure to give tert-butyl {2-(4-
chlorophenylsulfonamido)ethyl}carbamate 4c as a white solid (450 mg, 81 %); mp 129-132 
°C; IR (nujol) νmax /cm
-1
 3396 (NH), 3276 (NH), 1683 (CO), 1458 (Ar-C), 1377 (CH2), 
1345 (S=O), 1153 (C-O); 
1
H NMR (400MHz, CDCl3): δ (ppm) 1.42 (9H, s, C(CH3)3), 3.05 
(2H, q, J = 5.6 Hz, NHCH2CH2NH), 3.22 (2H, q, J = 5.6 Hz, NHCH2CH2NH), 4.88 (1H, s, 
NH), 5.45 (1H, s, NH), 7.29 (2H, d, J = 9.0 Hz, ArH), 7.74 (2H, d, J = 9.0 Hz, ArH); 
13
C 
NMR (CDCl3): δ (ppm) 28.3 (CH3)3, 40.2 (CH2), 43.9 (CH2), 80.1 (quat.,CMe3), 128.4 (2 × 
CH), 129.4 (2 × CH), 138.3 (quat.), 139.1 (quat.), 156.6 (C=O); ESIMS m/z  375 (18), 359 
(39 %), 357 (MNa
+
, 100), 300 (10).                           
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3.3.2.6 Preparation of N-(2-aminoethyl)-4-chlorophenylsulfonamide 
trifluoroacetate salt 1c 
 
tert-Butyl (2-(4-chlorophenylsulfonamido)ethyl)carbamate 4c (155 mg, 0.46 mmol) was 
dissolved in DCM (3.5 ml) and TFA (0.5 ml) was added to the solution. The reaction 
mixture was stirred in ice for 2 hours until the reaction was complete (as indicated by 
TLC), and the excess TFA was evaporated to give white crystals of N-(2-aminoethyl)-4-
chlorophenylsulfonamide trifluoroacetate 1c (140 mg, 90 %); mp 151-156 °C (Found: 
MH
+
, 235.0303. Calc. for C8H11ClN2O2S: MH, 235.0302); IR (nujol) ν max/cm
-1
 3087 (NH), 
1460 (Ar-C), 1341 (S=O); 
1
H NMR (400MHz, d6-DMSO): δ (ppm) 2.82 (2H, t, J = 6.0 Hz, 
NHCH2CH2NH), 2.92 (2H, t, J = 6.0 Hz, NHCH2CH2NH), 7.70 (2H, d, J = 8.8 Hz, ArH), 
7.79 (2H, d, J = 8.8 Hz, ArH); 
13
C NMR (d6-DMSO): δ (ppm) 39.8 (CH2), 118.2 (CF3), 
128.8 (2 × CH), 129.9 (2 × CH), 138.1 (quat.), 138.8 (quat.), 161.9 (C=O); ESIMS m/z 257 
(MNa
+
, 8 %), 237 (52),  235 (MH
+
, 100), 218 (8).                                                                                                  
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3.3.2.7 Preparation of tert-butyl {2-(4-nitrophenyl)-
sulfonamido}ethylcarbamate 4d 
 
4-Nitrophenylsulfonyl chloride (833 mg, 3.75 mmol) was added to a mixture of N-Boc-
ethylenediamine (0.49 ml, 3.12 mmol) and diisopropylethylamine (0.65 ml, 4.68 mmol) in 
DCM (5 ml), and the mixture was stirred for 24 hours at room temperature, under nitrogen. 
When the reaction was complete (as indicated by TLC), the reaction mixture was diluted 
with DCM (10 ml) and washed with water (2 × 20 ml), then brine (2 × 25 ml). The organic 
layers were dried over anhydrous Na2SO4, filtered, and evaporated under reduced pressure. 
The organic extract was purified by column chromatography on silica, eluting with ethyl 
acetate-hexane (0:100 to 50:50), to yield tert-butyl {2-(4-nitrophenyl)-
sulfonamido}ethylcarbamate 4d as a yellow solid (687 mg, 82.5 %); mp 158-163 °C; IR 
(nujol) νmax/cm
-1
 3375 (NH), 3276 (NH), 1693 (CO), 1458 (Ar-C), 1338 (S=O); 
1
H NMR 
(400MHz, CD3COCD3): δ (ppm) 1.37 (9H, s, C(CH3)3), 3.10 (2H, t, J = 6.0 Hz, 
NHCH2CH2NH), 3.17 (2H, q, J = 6.0 Hz, NHCH2CH2NH), 6.07 (1H, s, NH), 6.95 (1H, s, 
NH), 8.13 (2H, d, J = 9.0 Hz, ArH), 8.44 (2H, d, J = 9.0 Hz, ArH); 
13
C NMR 
(CD3COCD3): δ (ppm) 27.6 (CH3)3, 40.1 (CH2), 43.1 (CH2), 78.1 (quat., CMe3), 124.3 (2 × 
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CH), 128.3 (2 × CH), 146.3 (quat.), 150.1 (quat.), 155.9 (C=O); ESIMS m/z 369 (18 %), 
368 (MNa
+
, 100), 311 (13), 246 (3).   
3.3.2.8 Preparation of N-(2-aminoethyl)-4-nitrophenylsulfonamide 
trifluoroacetate salt 1d  
 
tert-Butyl {2-(4-nitrophenyl)-sulfonamido}ethylcarbamate 4d (120 mg, 0.35 mmol) was 
dissolved in DCM (3.5 ml) and TFA (0.5 ml) was added to the solution. The reaction 
mixture was stirred in ice for 2 hours until the reaction was complete, the mixture was left 
to allow the excess of TFA to evaporate to give white crystals of N-(2-aminoethyl)-4-
nitrophenylsulfonamide trifluoroacetate 1d (100 mg, 83 %); mp 158-162 °C (Found: MH
+
, 
246.0544. Calc. for C8H11N3O4S: MH, 246.0543); IR (nujol) ν max/cm
-1
 3087 (NH), 1460 
(Ar-C), 1340 (S=O); 
1
H NMR (400MHz, d6-DMSO): δ (ppm) 2.85 (2H, broad s, 
NHCH2CH2NH3), 2.98 (2H, q, J = 6.4 Hz, NHCH2CH2NH), 8.04 (2H, d, J = 9.2 Hz, ArH), 
8.30 (1H, t, J = 6.4 Hz, NH), 8.43 (2H, d, J = 9.2 Hz, ArH); 
13
C NMR (d6-DMSO): δ (ppm) 
39.8 (CH2), 117.9 (CF3), 125.1 (2 × CH), 128.8 (2 × CH), 145.2 (quat.), 150.1 (quat.), 
161.8 (C=O); ESIMS m/z 247 (19 %), 246 (MH
+
, 100), 229 (7). 
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3.3.2.9 Preparation of tert-butyl {2-(2-nitrophenyl)-
sulfonamido}ethylcarbamate 4e                                            
 
2-Nitrophenylsulfonyl chloride (1.25 g, 5.62 mmol) was added to a mixture of N-Boc-
ethylenediamine (0.74 ml, 4.68 mmol) and diisopropylethylamine (1.23 ml, 7 mmol) in 
DCM (10 ml), and the mixture was stirred for 24 hours at room temperature, under 
nitrogen. When the reaction was complete (as indicated by TLC), the reaction mixture was 
diluted with DCM (20 ml) and washed with water (2 × 25 ml), then brine (2 × 30 ml) 
before being dried with anhydrous Na2SO4. The organic extract was purified by column 
chromatography on silica, eluting with ethyl acetate-hexane (0:100 to 50:50), to yield tert-
butyl {2-(2-nitrophenyl)sulfonamido}ethylcarbamate 4e as a brown liquid (990 mg, 79 %);  
IR (nujol) νmax /cm
-1
 3372 (NH), 1688 (CO), 1458 (Ar-C), 1377 (CH2), 1336 (S=O); 
1
H 
NMR (400MHz, CDCl3): δ (ppm) 1.42 (9H, s, C(CH3)3), 3.22 (2H, broad s, 
NHCH2CH2NH), 3.28 (2H, q, J = 5.3 Hz, NHCH2CH2NH), 4.87 (1H, s, NH), 5.74 (1H, s, 
NH) 7.74 (2H, m, ArH), 7.86 (1H, m, ArH), 8.12 (1H, m, ArH); 
13
C NMR (CDCl3): δ 
(ppm) 14.1 (CH3)3, 40.3 (CH2), 43.8 (CH2), 60.4 (quat.), 125.4 (CH), 130.9 (CH), 132.2 
94 
 
(CH), 133.6 (CH), 135.3 (quat.), 148.1 (quat.), 156.1 (C=O); ESIMS m/z 369 (17 %), 368 
(MNa
+
, 100), 312 (9), 246 (11).                                                                                         
3.3.2.10 Preparation of N-(2-aminoethyl)-2-nitrophenylsulfonamide 
trifluoroacetate salt 1e 
 
tert-Butyl {2-(2-nitrophenyl)sulfonamido}ethylcarbamate 4d, (500 mg, 1.45 mmol) was 
dissolved in DCM (5 ml) and TFA (0.75ml) was added to the solution. The reaction 
mixture was stirred in ice for 2 hours until the reaction was complete, the mixture was left 
to allow the excess of TFA to evaporate to give a brown solid of N-(2-aminoethyl)-2-
nitrophenylsulfonamide trifluoroacetate 1e (400 mg, 80 %); mp 159-163 °C (Found: MH
+
, 
246.0543. Calc. for C8H11N3O4S: MH, 246.0543); IR (nujol) νmax/cm
-1
 3087 (NH), 1460 
(Ar-C), 1377 (CH2), 1343 (S=O), 1166 (S=O); 
1
H NMR (400MHz, d6-DMSO): δ (ppm) 
2.88 (2H, t, J = 6.4 Hz, NHCH2CH2NH), 3.09 (2H, t, J = 6.4 Hz, NHCH2CH2NH), 7.89 
(2H, m, ArH), 8.00 (2H, m, ArH); 
13
C NMR (d6-DMSO): δ (ppm) 39.7 (CH2), 117.8 (CF3), 
125.2 (2 × CH), 128.8 (2 × CH), 145.3 (quat.), 150.1 (quat.), 161.8 (C=O); ESIMS m/z   
430 (63), 247 (13 %), 246 (MH
+
, 100), 186 (7). 
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3.3.2.11 Preparation of tert-butyl {2-(4-
acetamidophenyl)sulfonamide}ethylcarbamate 4f 
 
4-Acetamidophenylsulfonyl chloride (730 mg, 3.12 mmol) was added to a mixture of N-
Boc-ethylenediamine (0.5 ml, 3.12 mmol) and diisopropylethylamine (0.65 ml, 3.75 mmol) 
in DCM (10 ml) and the mixture was stirred for 24 hours at room temperature, under 
nitrogen. When the reaction was complete, the reaction mixture was diluted with DCM (15 
ml) and washed with water (2 × 25 ml), then brine (2 × 25 ml), then dried using anhydrous 
Na2SO4 to yield tert-butyl {2-(4-acetamidophenyl)sulfonamido}ethylcarbamate 4f as a 
yellowish-white solid (700 mg, 95 %); mp 152-155 °C; IR (nujol) νmax/cm
-1
 3365 (NH), 
3280 (NH), 3197 (NH), 1683 (CONH), 1645 (C=O), 1461 (Ar-C), 1377 (CH2), 1340 
(S=O), 1153 (C-O); 
1
H NMR (400MHz, CD3COCD3): δ (ppm) 1.37 (9H, s, C(CH3)3, 2.12 
(3H, s, CH3), 2.75 (1H, s, NH), 2.85 (2H, q, J = 6.4 Hz, NHCH2CH2NH), 3.03 (2H, q, J = 
6.4 Hz, NHCH2CH2NH), 7.65 (2H, d, J = 9.0 Hz,  ArH), 7.71 (2H, d, J = 9.0 Hz, ArH), 
9.45 (1H, s, NH); 
13
C NMR (CD3COCD3): δ (ppm) 23.4 (CH3), 27.6 (CH3)3, 40.7 (CH2), 
43.6 (CH2), 78.8 (C-O), 118.9 (2 × CH), 127.8 (2 × CH), 134.7 (quat.), 143.4 (quat.), 156.5 
(quat.), 169.1 (quat.); ESIMS m/z 381 (19 %), 380 (MNa
+
, 100), 258 (19), 130 (14).                                                                                              
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3.3.2.12 Preparation of N-{4-(N-(2-
aminoethylsulfamoyl)phenyl}acetamide trifluoroacetate salt 1f 
 
tert-Butyl {2-(4-acetamidophenyl)sulfonamide}ethyl carbamate 4f (250 mg, 0.70 mmol) 
was dissolved in DCM (5 ml) and TFA (0.75 ml) was added to the solution. The reaction 
mixture was stirred in ice for 2 hours until the reaction was complete, the mixture was left 
to allow the excess of TFA to evaporate to give a white solid of N-{4-(N-(2- 
aminoethylsulfamoyl)phenyl}acetamide trifluoroacetate 1f  (240 mg, 96 %); mp 86-93 °C; 
IR (nujol) νmax/cm
-1
 3244 (NH), 3176 (NH), 3112 (NH), 1716 (CONH), 1642 (C=O), 1463 
(Ar-C), 1377 (CH2), 1341 (S=O), 723 (Ar-H); 
1
H NMR (400MHz, CD3COCD3): δ (ppm)  
2.10 (3H, s, CH3), 3.31 (2H, t, J = 5.6 Hz, NHCH2CH2NH), 3.89 (2H, t, J = 5.6 Hz, 
NHCH2CH2NH), 7.77 (2H, d, J = 8.8 Hz, ArH), 7.81 (2H, d, J = 8.8 Hz, ArH); 
13
C NMR 
(CD3COCD3): δ (ppm) 23.3 (CH3), 40.4 (CH2), 48.3 (CH2), 117.8 (CF3), 118.2 (2 × CH), 
128.1 (2 × CH), 134.5 (quat.), 143.1 (quat.), 162.5 (C=O), 168.8 (CONH.); ESIMS m/z 280 
MNa
+
 (10), 259 (22 %), 258 (MH
+
, 100), 216 (9).                                                 
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3.3.2.13 Preparation of 4-amino-N-(2-aminoethyl)benzenesulfonamide 
1g 
 
Aq. hydrochloric acid (2M, 5 ml) was added to N-(4-(N-(2-
aminoethyl)sulfamoyl)phenyl)acetamide 1f (200 mg, 0.78 mmol) and the solution was 
allowed to reflux for 24 hours. When the reaction was complete, the pH  of the solution was 
adjusted to 10, then it was extracted with EtOAc (2 × 25 ml), followed by brine (2 × 25 
ml), and dried over anhydrous Na2SO4 to yield 4-amino-N-(2-
aminoethyl)benzenesulfonamide 1g, as a pure brown solid (70 mg, 35 %); mp 101-105 °C 
(Found: MH
+
, 216.0803 Calc. for C8H13N3O2S: MH, 216.0801); IR (nujol) νmax/cm
-1
 3175 
(NH), 1460 (Ar-C), 1377 (CH2), 1345 (S=O); 
1
H NMR (400MHz, CD3COCD3): δ (ppm) 
3.02 (2H, q, J = 5.6 Hz, NHCH2CH2NH), 3.19 (2H, t, J = 5.6 Hz, NHCH2CH2NH), 5.41 
(1H, s, NH), 5.94 (1H, s, NH), 6.72 (2H, d, J = 8.6 Hz, ArH), 7.51 (2H, d, J = 8.6 Hz, 
ArH); 
13
C NMR (CD3COCD3): δ (ppm) 43.8 (CH2), 50.2 (CH2), 113.0 (2 × CH), 128.7 (2 × 
CH), 128.9 (quat.), 152.3 (quat.); ESIMS m/z 238 MNa
+
 (47), 217 (11 %), 216 (MH
+
, 100), 
156 (7).   
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3.3.3 Coupling of sulfonamides with β-alanine 
3.3.3.1 Synthesis of tert-butyl [3-oxo-3-{2-
(phenylsulfonamido)ethyl}amino]propylcarbamate 7a  
 
N-(2-Aminoethyl)benzenesulfonamide 1a  (160 mg, 0.81 mmol), and t-Boc-β-alanine 
(153.5 mg, 0.81 mmol) were dissolved in DMF (5 ml), then EDC (155.5 mg, 0.81 mmol), 
HOBt (109.5 mg, 0.81 mmol), and DIPEA (1 ml, 5.6 mmol) were added to the mixture. 
The clear solution was stirred at room temperature for 24 h and after the reaction was 
complete, the DMF was removed in vacuo, then the residue was partitioned between 
EtOAc (200 ml) and water (200 ml ). The separated organic layer was washed with 5%  aq. 
NaHCO3 (2 × 20 ml), 0.5 M citric acid (2 × 10 ml), then brine (2 × 25 ml). The organic 
layer was dried over Na2SO4 and evaporated to give tert-butyl [3-oxo-3-{(2-
phenylsulfonamido)ethyl}amino]propylcarbamate 7a (150 mg, 93 %) as a yellowish-white 
liquid; IR (nujol) νmax/cm
-1
 3341 (NH), 3178 (NH),1728 (C=O), 1650 (C=O), 1460 (Ar-C), 
1377 (CH2), 1342 (S=O), 1156 (C-O); 
1
H NMR (400MHz, d6-DMSO): 1.30 (9H, s, 
C(CH3)3), 2.69 (2H, q, J = 6.0 Hz, NHCH2CH2NH), 2.90  (2H, q, J = 6.0 Hz, 
NHCH2CH2NH), 3.28-3.32 (4H, m broad), 6.74 (1H, t, J = 6.0 Hz, NH), 7.60 (3H, m,  
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ArH), 7.74 (2H, dt, J = 6.8, 1.6 Hz, ArH);
 13
C NMR (d6-DMSO): δ (ppm) 28.5 (CH3)3, 31.1 
(CH2), 38.1 (CH2), 39.5 (CH2), 42.6 (CH2), 78.2 (C-O), 126.8 (2 × CH), 128.8  (2 × CH), 
130.3 (CH), 140.7 (quat.), 155.8 (quat.), 165.1 (quat.); ESIMS m/z 395 (18 %), 394 (MNa
+
, 
100), 329 (15), 291 (11).    
3.3.3.2 Preparation of 3-amino-N-{2-
(phenylsulfonamido)ethyl}propanamide trifluoroacetate 8a 
 
tert-Butyl [3-oxo-3-{(2-phenylsulfonamido)ethyl}amino}carbamate 7a (130 mg, 0.35 
mmol) was dissolved in DCM (3.5 ml) and TFA (0.5 ml) was added to the solution. The 
reaction mixture was stirred in ice bath for 2 hours until the reaction was complete, then the 
mixture was left to allow the excess of TFA to evaporate to give 3-amino-N-{2-
(phenylsulfonamido)ethyl}propanamide trifluoroacetate 8a (100 mg, 77 %) as a brown 
solid; mp 124-128 °C; (Found: MH
+
, 272.0990. Calc. for C11H17N3O3S: MH, 272.0988); IR 
(nujol) νmax/cm
-1
 3284 (NH), 3151 (NH), 1670 (CONH), 1458 (Ar-C), 1377 (CH2),1338 
(S=O), 1166 (S=O), 721 (Ar-H); 
1
H NMR (400MHz, d6-DMSO): 2.36 (2H, t, J = 6.4 Hz, 
COCH2CH2), 2.74 (2H, q, J = 6.4 Hz, COCH2CH2NH3), 2.91 (2H, q, J = 6.34 Hz, 
NHCH2CH2NH), 3.05 (2H, q, J = 6.4 Hz, NHCH2CH2NH), 7.57 (3H, m, ArH), 7.75 (2H, 
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dt, J = 6.8, 1.6 Hz, ArH), 8.09 (1H, t, J = 6.4 Hz, NH); 
13
C NMR (d6-DMSO): δ (ppm) 32.4 
(CH2), 35.6 (CH2), 38.9 (CH2), 42.2 (CH2), 118.2 (CF3), 126.8 (2 × CH), 129.6 (2 × CH), 
132.9 (CH), 140.7 (quat.), 158.5 (quat.), 161.8 (C=O); ESIMS m/z 294 (MNa
+
, 13), 272 
(MH
+
, 100),  201 (18).               
3.3.3.3 Synthesis of tert-butyl [3-{2-(4-
methylphenylsulfonamido)ethyl}amino]-3-
oxopropylcarbamate 7b 
 
N-(2-Aminoethyl)-4-methylphenylsulfonamide trifluoroacetate 1b (225 mg, 1 mmol), and 
t-Boc-β-alanine (198 mg, 1 mmol) were dissolved in DMF (5 ml), then EDC (201 mg, 1 
mmol), HOBt (142 mg, 1 mmol), and DIPEA (1.5 ml, 8.5 mmol) were added to the 
mixture. The clear solution was stirred at room temperature for 24 hours, and after the 
reaction was complete the solvent was removed under vacuum, the residue was partitioned 
between EtOAc (200 ml) and water (200 ml). The organic layer was washed with 5% aq. 
NaHCO3 (2 × 20 ml), 0.5 M citric acid (2 × 10 ml), then brine (2 × 25 ml), then dried over 
Na2SO4 to give tert-butyl [3-{2-(4-methylphenylsulfonamido)ethyl}amino]-3-
oxopropylcarbamate 7b (200 mg, 88 %) as a white solid; mp 123-125 °C; IR (nujol) 
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νmax/cm
-1
 3334 (NH), 3274 (NH), 3178 (NH), 1635 (CONH),  1340 (S=O), 1458 (Ar-C), 
1377 (CH2), 1157 (C-O), 721 (Ar-H); 
1
H NMR (400MHz, d6-DMSO): 1.31 (9H, s, 
C(CH3)3), 2.12 (2H, t, J = 7.4 Hz, CH2CO), 2.35 (3H, s, CH3), 2.69 (2H, q, J = 6.4 Hz, 
CH2), 3.01 (4H, m, CH2CH2), 6.68 (1H, t, J = 5.4 Hz, NH) 7.35 (2H, d, J = 8.0 Hz, Ar-H), 
7.54 (1H, t, J = 6.0 Hz, NH), 7.62 (2H, d, J = 8.0 Ar-H), 7.81 (1H, t, J = 5.6 Hz, NH); 
13
C 
NMR (d6-DMSO): δ (ppm) 21.4 (CH3), 28.65 (CH3)3, 36.15 (CH2), 37.0 (CH2), 38.8 (CH2), 
42.3 (CH2), 77.8 (quat.), 126.9 (2 × CH), 130.0 (2 × CH), 137.8 (quat.), 143.3 (quat.), 155.8 
(C=O), 170.8 (C=O); ESIMS m/z 408 (MNa
+
, 100), 386 (MH
+
, 40 %), 330 (15), 286 (37). 
3.3.3.4 Preparation of 3-amino-N-{2-(4-
methylphenylsulfonamido)ethyl}propanamide trifluoroacetate 
8b 
 
tert-Butyl [3-{2-(4-methylphenylsulfonamido)ethyl}amino]-3-oxopropylcarbamate 7b (165 
mg, 0.43 mmol) was dissolved in DCM (3.5 ml) and TFA (0.5 ml) was added to the 
solution. The reaction mixture was stirred in ice bath for 2 hours until the reaction was 
complete, and the mixture was left to allow the excess of TFA to evaporate to give 3-
amino-N-{2-(4-methylphenylsulfonamido)ethyl}propanamide trifluoroacetate 8b (100 mg, 
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60 %) as a brown liquid; (Found: MH
+
, 286.1221. Calc. for C12H19N3O3S: MH, 286.1219); 
IR (nujol) νmax/cm
-1
 3290 (NH), 1725 (C=O), 1461 (Ar-C), 1377 (CH2), 1335 (S=O), 721 
(Ar-H); 
1
H NMR (400MHz, d6-DMSO): 2.30 (3H, s, CH3), 2.35 (2H, t, J = 6.8 Hz, 
NHCH2CH2NH), 2.71 (2H, t, J = 6.4 Hz, CH2CH2), 2.91 (2H, q, J = 6.8 Hz, CH2), 3.04 
(2H, t, J = 6.8 Hz, NH), 7.34 (2H, d, J = 8.4 Hz, Ar-H), 7.40  (1H, d, J = 8.4 Hz, NH), 7.59 
(2H, d, J = 8.4 Hz, Ar-H), 7.73 (1H, d, J = 8.4 Hz, NH); 
13
C NMR (d6-DMSO): δ (ppm) 
21.3 (CH3), 32.4 (CH2), 35.6 (CH2), 38.9 (CH2), 42.2 (CH2), 118.1 (CF3), 126.9 (2 × CH), 
139.8 (2 × CH), 137.8 (quat.), 143.5 (quat.), 161.8 (C=O), 169.7 (C=O); ESIMS m/z 308 
(MNa
+
, 17 %), 286 (MH
+
, 100), 215 (15),. 
3.3.3.5 Synthesis of tert-Butyl [3{2-(4-
chlorophenylsulfonamido)ethyl}amino]-3-oxopropylcarbamate 
7c 
 
N-(2-Aminoethyl)-4-chlorophenylsulfonamide trifluoroacetate 1c (230 mg, 0.98 mmol), 
and t-Boc-β-alanine (185.5 mg, 0.9799 mmol) were dissolved in DMF (7 ml) then EDC 
(188 mg, 0.98 mmol), HOBt (132.5 mg, 0.98 mmol), and DIPEA (1.5 ml, 8.5 mmol) were 
added to mixture. The clear solution was stirred at room temperature for 24 hours and after 
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the reaction was complete, the DMF was removed in vacuo, then the residue was 
partitioned between EtOAc (200 ml) and water (200 ml). The organic layer was dried over 
Na2SO4 and evaporated and the residue was purified by column chromatography on silica, 
eluting with ethyl acetate-hexane (0:100) to ethyl acetate-hexane (50:50), to yield tert-butyl 
[3-{(2-(4-chlorophenylsulfonamido)ethyl}amino]-3-oxopropylcarbamate 7c as a white 
solid (120 mg, 52 %); mp 118-122 °C, IR (nujol) νmax/cm
-1
 3290 (NH), 1725 (C=O), 1692 
(C=O), 1461 (Ar-C), 1345 (S=O), 1377 (CH2), 1160 (S=O), 721 (Ar-H); 
1
H NMR 
(400MHz, d6-DMSO): 1.31 (9H, s, (CH3)3), 2.12 (2H, t, J = 7.2 Hz, CH2CO), 2.72 (2H, t, J 
= 6.8 Hz, CH2), 3.00 (4H, m, CH2CH2), 6.68 (1H, s, NH), 7.64 (2H, d, J = 8.8 Hz, ArH), 
7.74 (2H, d, J = 8.8 Hz, ArH), 7.83 (1H, t, J = 5.6 Hz, NH); 
13
C NMR (d6-DMSO): δ (ppm) 
28.6 (CH3)3, 36.1 (CH2), 37.05 (CH2), 38.8 (CH2), 42.3 (CH2), 77.9 (quat.), 128.8 (2 × CH), 
129.8 (2 × CH), 137.6 (quat.), 139.6 (quat.), 155.8 (C=O.), 170.9 (C=O); ESIMS m/z  429 
(35 %), 428 (MNa
+
, 100), 406 (MH
+
, 40 %), 349 (24). 
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3.3.3.6 Preparation of 3-amino-N-{2-(4-
chlorophenylsulfonamido)ethyl}propanamide trifluoroacetate 
8c 
 
The tert-butyl [3-{(2-(4-chlorophenylsulfonamido)ethyl}amino]-3-oxopropylcarbamate 7c 
(100 mg, 0.25 mmol) was dissolved in DCM (3.5 ml) and TFA (0.5 ml) was added to the 
solution, the reaction mixture was stirred in an ice bath for 2 hours until the reaction was 
complete, and the mixture was left to allow the excess of TFA to evaporate to give 3-
amino-N-{2-(4-chlorophenylsulfonamido)ethyl}propanamide trifluoroacetate 8c (100 mg, 
100 %) as a brown liquid; (Found: MH
+
, 306.0675. Calc. for C11H16ClN3O3S: MH, 
306.0673); IR (nujol) νmax/cm
-1
 3160 (NH), 1683 (C=O), 1458 (Ar-C), 1375 (CH2), 1346 
(S=O), 720 (Ar-H); 
1
H NMR (400MHz, d6-DMSO): 2.36 (2H, t, J = 6.8 Hz, CH2), 2.75 
(2H, t, J = 6.8 Hz, CH2), 2.91 (2H, q, J = 6.8 Hz, CH2), 3.04 (2H, t, J = 6.8 Hz, CH2), 7.61 
(2H, d, J = 8.4 Hz, ArH), 7.67 (1H, d, J =8.8 Hz, NH), 7.73 (2H, d, J = 8.4 Hz, ArH), 7.88 
(1H, d, J = 8.8 Hz, NH); 
13
C NMR (d6-DMSO): δ (ppm) 32.4 (CH2), 35.6 (CH2), 38.9 
(CH2), 42.2 (CH2), 118.3 (CF3), 128.8 (2 × CH), 129.8 (2 × CH), 137.7 (quat.), 139.6 
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(quat.), 162.5 (C=O), 169.9 (C=O); ESIMS m/z 377 (22), 307 (37 %), 306 (MH
+
, 100), , 
235 (10). 
3.3.3.7 Synthesis of tert-butyl [3-{2-(4-
nitrophenylsulfonamido)ethyl}amino]-3-oxopropylcarbamate 
7d 
 
N-(2-aminoethyl)-4-nitrophenylsulfonamide trifluoroacetate salt 1d  (170 mg, 0.7 mmol), 
and t-Boc-β-alanine (131 mg, 0.7 mmol) were dissolved in DMF (8 ml), then EDC (132.8 
mg, 0.69 mmol), HOBt (93.63 mg, 0.69 mmol), and DIPEA (1.5 ml, 8.5 mmol) were added 
to the mixture. The clear solution was stirred at room temperature for 24 hours and after the 
reaction was complete the solvent was removed in vacuo and the residue was partitioned 
between EtOAc (200 ml) and water (150 ml). The organic layer was washed with 5% aq. 
NaHCO3 (2 × 20 ml), 0.5 M citric acid (2 × 10 ml), then brine (2 × 25 ml), then dried over 
Na2SO4 and evaporated to give tert-butyl {3-{2-(4-nitrophenylsulfonamido)ethyl}amino]-
3-oxopropylcarbamate 7d (160 mg, 94 %) as a brown liquid;  IR (nujol) νmax/cm
-1
 3315 
(NH), 3262 (NH), 1680 (C=O), 1651 (CONH),1450 (Ar-C), 1390 (CH2), 1341 (S=O); 
1
H 
NMR (400MHz, d6-DMSO): 1.31 (9H, s, (CH3)3, 2.12 (2H, t, J = 7.4 Hz, CH2), 2.79 (2H, t, 
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J = 6.8 Hz, CH2), 3.03 (4H, m, CH2CH2), 6.68 (1H, t, J = 5.2 Hz, NH), 7.85 (1H, t, J = 5.6 
Hz, NH), 7.99  (2H, d, J = 9.0 Hz, ArH), 8.03 (1H, s, NH), 8.38 (2H, d, J = 9.0 Hz, ArH); 
13
C NMR (d6-DMSO): δ (ppm) 28.6 (CH3)3, 36.2 (CH2), 37.0 (CH2), 38.8 (CH2), 42.3 
(CH2), 77.9 (quat.), 125.05 (2 × CH), 128.4 (2 × CH), 139.5 (quat.), 146.3 (quat.), 150.1 
(C=O), 171.05 (C=O); ESIMS m/z  436 (15), 418 (20 %), 417 (MH
+
, 100).  
3.3.3.8 Preparation of 3-amino-N-{2-(4-
nitrophenylsulfonamido)ethyl}propanamide 8d 
 
tert-Butyl {3-{2-(4-nitrophenylsulfonamido)ethyl}amino]-3-oxopropylcarbamate 7d (150 
mg, 0.36 mmol) was dissolved in DCM (3.5 ml) and TFA (0.5 ml) was added to the 
solution, the reaction mixture was stirred in ice bath for 2 hours until the reaction was 
complete, then the mixture was left to allow the excess of TFA to evaporate to give 3-
amino-N-{2-(4-nitrophenylsulfonamido)ethyl}propanamide trifluoroacetate 8d (130 mg, 86 
%) as a brown liquid; (Found: MH
+
, 317.0916. Calc. for C11H16N4O5S: MH, 317.0914); IR 
(nujol) νmax/cm
-1
 3200 (NH), 1727 (C=O), 1461 (Ar-C), 1377 (CH2), 1336 (S=O), 721 (Ar-
H); 
1
H NMR (400MHz, d6-DMSO): 2.35 (2H, t, J = 6.8 Hz, CH2), 2.81 (2H, t, J = 6.4 Hz, 
CH2), 2.90 (2H, t, J = 6.8 Hz, CH2), 3.04 (2H, t, J = 6.4 Hz, CH2), 7.97 (2H, d, J = 8.8 Hz, 
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ArH), 8.36 (2H, d, J = 8.8 Hz, ArH); 
13
C NMR (d6-DMSO): δ (ppm) 32.4 (CH2), 35.6 
(CH2), 39.0 (CH2), 42.2 (CH2), 117.9 (CF3), 125.1 (2 × CH), 128.4 (2 × CH), 146.3 (quat.), 
150.0 (quat.), 161.8 (C=O), 170.0 (C=O); ESIMS m/z 428 (MNa
+
, 100), 318 (15 %), 317 
(MH
+
, 100), 246 (12). 
3.3.3.9 Synthesis of tert-butyl {3-{2-(2-
nitrophenylsulfonamido)ethyl}amino]-3-oxopropylcarbamate 
7e  
 
N-(2-aminoethyl)-2-nitrophenylsulfonamide trifluoroacetate salt 1e (200 mg, 0.81 mmol), 
and t-Boc- β-alanine (155 mg, 0.81 mmol) were dissolved in DMF (10 ml), then EDC (156 
mg, 0.82 mmol), HOBt (110.16 mg, 0.81 mmol) , and DIPEA (2 ml, 11.33 mmol) were 
added to the mixture. The clear solution was stirred at room temperature for 24 hours and 
after the reaction was complete the solvent was removed in vacuo. The residue was 
partitioned between EtOAc (200 ml) and water (150 ml), then the organic layer was washed 
with 5%  aq. NaHCO3 (2 × 20 ml), 0.5 M citric acid (2 × 10 ml) , then brine (2 × 25 ml), 
dried over Na2SO4 and evaporated to give tert-butyl{3-{2-(2-
nitrophenylsulfonamido)ethyl}amino]-3-oxopropylcarbamate 7e (170 mg, 85 %) as a 
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yellowish-white liquid; IR (nujol) νmax/cm
-1
 3310 (NH), 1689 (C=O), 1410 (Ar-C), 1374 
(CH2); 
1
H NMR (400MHz, CDCl3): 1.37 (9H, s, (CH3)3),  2.30 (2H, t, J = 5.8 Hz, CH2), 
3.20 (2H, q, J = 5.8 Hz, CH2), 3.25 (2H, q, J = 6.4 Hz, CH2), 3.32 (2H, q, J = 6.4 Hz, CH2), 
5.86 (1H, s, NH), 6.81 (1H, s, NH), 7.30 (1H, s, NH), 7.89 (2H, m, ArH), 7.94 (1H, m, 
ArH), 8.10 (1H, m, ArH); 
13
C NMR (d6-DMSO): δ (ppm) 28.6 (CH3)3, 36.2 (CH2), 37.1 
(CH2), 38.8 (CH2), 42.3 (CH2), 77.9 (quat.), 124.8 (2 × CH), 129.7 (2 × CH), 146.2 (quat.), 
138.6 (quat.), 159.8 (C=O), 171.1 (C=O); ESIMS m/z 436 (17), 418 (18 %), 417 (MH
+
, 
100), 361 (60),. 
  3.3.3.10 Preparation of 3-amino-N-{2-(2-
nitrophenylsulfonamido)ethyl}propanamide 8e 
 
tert-Butyl{3-{2-(2-nitrophenylsulfonamido)ethyl}amino]-3-oxopropylcarbamate 7e (160 
mg, 0.0.38 mmol) was dissolved in DCM (3.5 ml) and TFA (0.5 ml) was added to the 
solution. The reaction mixture was stirred in ice bath for 2 hours until the reaction was 
complete, then the mixture was left to allow the excess of TFA to evaporate to give 3-
amino-N-{2-(2-nitrophenylsulfonamido)ethyl}propanamide trifluoroacetate 8e (100 mg, 
62.5 %) as a brown liquid; (Found: MH
+
, 317.0915. Calc. for C11H16N4O5S: MH, 
109 
 
317.0914); IR (nujol) νmax/cm
-1
 3229 (NH), 1461 (Ar-C), 1160 (S=O), 725 (Ar-H); 
1
H 
NMR (400MHz, d6-DMSO): 2.35 (2H, t, J = 6.8 Hz, CH2), 2.89 (4H, m, CH2CH2), 3.09 
(2H, t, J = 6.4 Hz, CH2), 7.81 (2H, m, ArH), 7.91 (2H, m, ArH); 
13
C NMR (d6-DMSO): δ 
(ppm) 32.4 (CH2), 35.6 (CH2), 39.1 (CH2), 42.3 (CH2), 118.1 (CF3), 124.7 (CH), 129.7 
(CH), 133.0 (CH), 134.5 (CH), 148.2 (quat.), 158.5 (quat.), 161.9 (C=O), 170.1 (C=O); 
ESIMS m/z  339 (13), 318 (14 %), 317 (MH
+
, 100), 246 (23). 
3.4.1 Coupling of Ciprofloxacin with 
t
Boc-β-alanine 10 
 
Ciprofloxacin (262.6 mg, 0.79 mmol) 9 and t-Boc-β-alanine (150 mg, 0.79 mmol) were 
dissolved in DMF (5 ml), then EDC (152 mg, 0.79 mmol), and HOBt (107 mg, 0.79 mmol) 
were added to the mixture. The clear solution was cooled to 0 ºC for 20 minutes then the 
mixture was stirred at room temperature for 24 hours. After the reaction was complete, the 
solvent was removed in vacuo, then the residue was partitioned between EtOAc (200 ml) 
and water (150 ml), the organic layer was washed with 5 % aq. NaHCO3 (2 × 20 ml), 0.5 M 
citric acid (2 × 10 ml), then brine (2 × 25 ml), dried over Na2SO4 and evaporated to give 
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N''-(
t
Boc-β-alanyl)ciprofloxacin 10 (240 mg, 91 %) as a white solid; mp 201-206 °C; IR 
(nujol) νmax/cm
-1
 3423 (NH), 3176 (OH), 1782 (C=O),1456 (Ar-C), 1377 (CH2), 1160 (CO) 
730 (Ar-H); 
1
H NMR (400MHz, d6-DMSO): 1.14 (2H, d, J = 6.8 Hz, CH2),  1.27 (2H, m, 
CH2), 1.33 (9H, s, (CH3)3), 2.49 (2H, m, CH2), 3.13 (2H, q, J = 6.4 Hz, CH2), 3.27 (2H, m, 
CH2), 3.62 (4H, m, (CH2)2), 3.87 (1H, m, CH), 6.71 (1H, t, J = 6.0 Hz, NH), 7.52 (1H, d, 
JFH = 7.2 Hz, Ar-H), 7.87 (1H, d, JFH = 13.2 Hz, Ar-H), 8.63 (1H, s, Ar-H); 
13
C NMR (d6-
DMSO): δ (ppm) 8.6 (CH2)2, 28.6 (3 × CH3), 33.2 (CH2), 36.3 (CH), 36.8 (CH2), 44.9 
(CH2), 49.5 (CH2), 49.9 (CH2), 78.1 (quat.), 107.0 (quat.), 107.7 (quat.), 111.3 (CH), 115.5 
(CH), 119.2 (2 × CH), 139.5 (quat.), 145.3 (CH), 148.5 (quat.), 152.1 (quat.), 153.4 (quat.), 
155.8 (C=O), 166.3 (C=O), 169.7 (C=O.), 176.8 (C=O). ESIMS m/z 503 (MH
+
, 100), 494 
(12), 476 (10). 
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3.4.2 Synthesis of N''-(β-alanyl)ciprofloxacin 11 
 
N''-(
t
Boc-Alanyl)ciprofloxacin 10 (200 mg, 0.4 mmol) was dissolved in DCM (3.5 ml) and 
TFA (0.5 ml) was added to the solution. The reaction mixture was stirred in an ice bath for 
2 hours until the reaction was complete, then the mixture was left to allow the excess of 
TFA to evaporate to give N''-(β-alanyl)ciprofloxacin 11 (190 mg, 95 %) as a yellow liquid; 
(Found: MH
+
, 385.1670. Calc. for C20H23FN4O4S: MH, 385.1670); IR (nujol) νmax/cm
-1
 
3402 (NH), 3176 (OH), 1782 (C=O),1456 (Ar-C), 1377 (CH2), 1168 (CO), 723 (Ar-H); 
1
H 
NMR (400MHz, d6-DMSO): 1.15 (2H, m, CH2), 1.28 (2H, q, J = 6.8 Hz, CH2), 2.71 (2H, t, 
J = 6.4 Hz, CH2), 3.01 (2H,  m,  CH2), 3.29 (2H, m, CH2), 3.34 (2H, m, CH2), 3.62 (2H, m, 
CH), 3.68 (2H, m, CH), 3.78 (1H, m, CH), 7.53 (1H, d, JHF = 7.6 Hz, Ar-H), 7.71 (1H, 
broad s, NH3), 7.89 (1H, d, JHF = 13.2 Hz, Ar-H), 8.63 (1H, s, Ar-H); 
13
C NMR (d6-
DMSO): δ (ppm) 8.0 (CH2)2, 30.1 (CH), 35.6 (CH2), 36.2 (CH2), 41.1 (CH2), 44.7 (CH2), 
107.1 (CH), 111.5 (quat.), 114.3 (CH), 117.2 (quat.), 118.4 (CF3), 120.1 (quat.), 139.5 
(quat.), 158.5 (CH), 158.9 (quat.), 159.2 (quat.), 162.2 (C=O), 166.3 (C=O), 168.8 (C=O), 
176.7 (C=O); ESIMS m/z 403 (MH
+
, 100), 332 (12). 
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3.5.1 Preparation of N
7
-(3-phthalimidopropyl)theophylline  14 
 
Theophylline (3.6 g, 20 mmol) was added to dry DMF (50 ml) then K2CO3 (4.15 g, 30 
mmol) and N-(3-bromopropyl)phthalimide (6.7 g, 25 mmol) were added and the reaction 
mixture was stirred overnight at room temperature. The reaction mixture was cooled in ice 
for 2 hours, the white precipitate was collected by vacuum filtration then recrystallized 
from 50% H2O / acetic acid to yield N
7
-(3-phthalimidopropyl)theophylline 14 (5 g, 74 %) 
as a pure white solid; mp 260-262 °C; IR (nujol) νmax/cm
-1
 1782 (C=O), 1685 (C=O), 1456 
(Ar-C), 1377 (CH2), 1168 (CO), 723 (Ar-H); 
1
H NMR (400MHz, CDCl3): 2.29 (2H, q, J = 
6.4 Hz, CH2), 3.36 (3H, s, CH3), 3.55 (3H, s, CH3), 3.71 (2H, t, J = 6.0 Hz, CH2), 4.31 (2H, 
t, J = 6.4 Hz, CH2), 7.72 (2H, d, J = 8.6 Hz, Ar-H), 7.77 (1H, s, Ar-H), 7.83 (2H, d, J = 8.6 
Hz, Ar-H); 
13
C NMR (CDCl3): δ (ppm) 27.9 (CH2), 29.6 (CH3), 29.9 (CH3), 34.6 (CH2), 
44.4 (CH2), 106.7 (quat.), 123.2 (2 × CH), 131.7 (2 × CH), 134.0 (2 × quat.), 141.4 (CH), 
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148.9 (quat.), 151.6 (quat.), 168.5 (2 × quat.); ESIMS m/z 431 (32), 390 MNa
+
 (38), 369 
(29), 368 (MH
+
, 100).  
3.5.2  Preparation of N
7
-(3-aminopropyl)theophylline  13 
 
To a solution of N
7
-(3-phthalimidopropyl)theophylline 14 (1g, 2.72 mmol) in ethanol (10 
mL), hydrazine hydrate (98%, 2.5 mL)  was added and the reaction mixture was stirred at 
room temperature for 48 h. The solvent was removed under vacuum, then 1M aq. HCl (20 
ml) was added and the solution extracted with CHCl3 (2 x 10 ml). The aqueous layer was 
basified then extracted with CHCl3 (2 × 10 ml).  The organic layers were dried over 
Na2SO4, then evaporated to give N
7
-(3-aminopropyl)theophylline 13 (150 mg, 15 %) as a 
yellow solid; mp 80-85 °C; (Found: MH
+
, 238.1300. Calc. for C10H15N5O2: MH, 
238.1298); IR (nujol) νmax/cm
-1 
3310 (NH), 1720 (C=O), 1692 (C=O), 1377 (CH2); 
1
H 
NMR (400MHz, CDCl3): 1.97 (2H, q, J = 6.8 Hz, CH2), 2.69 (2H, t, J = 6.8 Hz, CH2), 3.39 
(3H, s, CH3), 3.57 (3H, s, CH3), 4.39 (2H, t, J = 6.8 Hz, CH2), 7.57 (1H, s, CH); 
13
C NMR 
(CDCl3): δ (ppm) 27.9 (CH2), 29.7 (CH3), 34.0 (CH3), 38.3 (CH2), 44.4 (CH2), 106.9 
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(quat.), 141.1 (CH), 148.8 (quat.), 151.6 (quat.), 155.1 (2 × quat.); ESIMS m/z 279 (15), 
239 (35), 238 (MH
+
, 100), 221 (70). 
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4. Biological activity tests 
4.1 Antimicrobial susceptibility tests  
Disc diffusion and micro-dilution assays were conducted in order to evaluate the 
antimicrobial activities of the synthesized compounds. 
4.1.1 Disc diffusion assay 
The disc diffusion assay is a simple and fast method used to test whether a specific 
bacterium is susceptible to an antimicrobial agent by measuring the zones of inhibition, 
which is the distance from the edge of a disc impregnated with the test agent to the edge of 
confluent growth, Figure 22. 
 
 
 
 
 
 
Figure 22 The zone of inhibition  
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4.1.2 Experimental procedure 
Sensitest agar (Oxoid, CM0409) medium was prepared and sterilized as per the 
manufacturer's instructions. 20 ml of the prepared medium was added to each sterile plastic 
Petri dish to ensure consistent plate depths, and was allowed to set for 20-30 minutes at 
room temperature. The prepared plates were stored at 2-8 ºC and used within 4 weeks of 
preparation. 
Bacteria to be tested were streaked onto the Sensitest agar plates which were then incubated 
overnight at 37 ºC. 
The sterile discs (Sigma, 74146) were placed onto a sterile glass Petri dish using sterile 
forceps, then 60 µl of the compound dissolved in acetone (highest volume which saturated 
the disc) at different concentrations (10,50, and 100 mg/ml) was loaded onto the sterile 
discs, Figure 23 . 
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Figure 23 Disc diffusion test for N-(2-aminoethyl)-4-nitrobenzenesulfonamide 
trifluoroacetate 1d, showing dose dependent response against PAO1 starting 
from lower row and from left to right 0, 10, and 20, and upper row from left 
50, and 100 mg/ml  
 
The bacterial suspensions for this work were prepared as follows: 
Sterile Phosphate Buffered Solution (PBS) was piptetted into a sterile falcone tubes, and 
inoculated with an inoculation loop of culture from overnight plate cultures. 
The bacterial suspension was poured onto a plate, which was gently rotated in order to 
ensure that full surface was covered, and the suspension was then poured onto the next 
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plate to inoculate it. This was repeated until all the plates were inoculated, the excess 
solution on the plates was removed using a 1ml pipette, and the inoculated plates were left 
to dry in a laminar flow cabinet for 5 minutes. 
The inoculated plates were labelled after the discs with different compound concentrations 
were placed onto segments, by gently pressing down to ensure that the discs were in place, 
and the plates were incubated at 37 ºC for 24-48 h. 
The zone of inhibition was measured at 24 h and 48 h time points. 
4.1.3 Results  
Twenty-seven synthesized compounds were tested in the disc diffusion assay against 
Pseudomonas aeruginosa strain PAO1 in order to evaluate their antibacterial effect, Figure 
24, and only six compounds showed anti-pseudomonal activity, although with different 
efficacy, Table 11. 
120 
 
 
Figure 24 Disc diffusion test for compounds 4a,4b, 4c, 4d, (first row), 1a, 1c, 1b, 4e, 
(second row), 4f, 1d, 1e (third row) against PAO1 at 0, 10, 50, and 100 
mg/ml. 
121 
 
Table 11 Disc diffusion assay results for the active compounds at 6 mg/ml on disc 
Compound Molecular Structure 
Zone of inhibition 
(mm) 
1a 
 
No growth on sterile 
disc 
1b 
 
2 
1c 
 
6 
1d 
 
9 
1e 
 
5.5 
122 
 
8e 
 
6.5 
 
N-(2-Aminoethyl)-4-nitrobenzenesulfonamide trifluoroacetate salt 1d, 3-amino-N-{2-(2-
nitrophenylsulfonamido)ethyl}propanamide trifluoroacetate 8e, and N-(2-aminoethyl)-4-
chlorobenzenesulfonamide 1c were the most effective compounds, while N-(2-
aminoethyl)benzenesulfonamide 1a was only slightly active, it was cytotoxic to the bacteria 
on the disc but it did not affect the bacteria in the medium, possibly due to poor diffusion 
from the disc. The six active compounds were also tested against the Gram negative 
Proteus vulgaris and Gram-positive Bacillus subtilis in order to evaluate the selectivity of 
their inhibition of the growth of P. aeruginosa, Table 12. For these tests, the concentrations 
of the solutions applied to the discs were 100 mg/ml.  
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Table 12 Disc diffusion results for active compounds against PAO1, B. subtilis, and P. 
vulgaris 
ID Molecular Structure 
Zone of inhibition in mm 
P. 
aeruginosa 
B. 
subtilis 
P. 
vulgaris 
8e 
 
6.8 0.3 1.3 
1c 
 
5.2 0.7 1.8 
1b 
 
2 0 0 
1d 
 
9 6.5 8.5 
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1a 
 
Clear disc 0 0 
1e 
 
5.5 4.5 4.5 
 
N-(2-Aminoethyl)-4-nitrobenzenesulfonamide trifluoroacetate 1d had the greatest 
antimicrobial effect against P. aeruginosa and the other organisms, while 3-amino-N-{2-(2-
nitrophenylsulfonamido)ethyl}propanamide 8e, N-(2-Aminoethyl)-4-
methylbenzenesulfonamide 1b and N-(2-aminoethyl)-4-chlorobenzenesulfonamide 1c 
trifluoroacetates exhibited the greatest selectivity against P. aeruginosa over B. subtilis and 
P. vulgaris Figure 25. N-(2-Aminoethyl)-4-methylbenzenesulfonamide 1b, and   N-(2-
aminoethyl)benzenesulfonamide 1a had very low anti-pseudomonal effect, with a zone of 
inhibition of 2 mm and clear disc, respectively . 
125 
 
 
Figure 25 Disc diffusion test for compounds 1c (first row), and 1b (second row) against 
B. subtilis (first column), P. vulgaris (second column), and PAO1 (third 
column) at 100 mg/ml concentration.   
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4.2.1 Minimum inhibitory concentration (MIC) or micro-dilution 
assay  
The minimum inhibitory concentration (MIC) is the lowest concentration of an 
antimicrobial agent that inhibits the growth of an organism and the MIC test determines the 
antimicrobial activity of a compound against a specific bacterium. 
4.2.2 Experimental procedure  
The bacteria to be tested were cultured onto Sensitest agar plates (Oxoid, CM0409) and 
incubated overnight at 37 °C. 
The active compounds were prepared at serial dilution in a final volume of 100 μl using 
iso-sensitest broth. 
The bacterial suspension was prepared at a turbidity of 0.5 Macfarland standard 
(approximately OD600 =0.05-0.1) which was obtained from a plate incubated overnight. 
100 μl of bacterial suspension was added into the appropriate wells of 96-well tissue culture 
plates, and 100 μl of the substance to be tested was added, so that compounds were tested at 
concentrations of 5000, 2500, 1250, 625, 312.5, 156.25, 78.125, 39.063, 19.531, 9.7656, 
4.8828, 0 μg/ml, and the plates were incubated at 37 °C for 24-48 h.  The MIC was 
determined as the lowest concentration of antimicrobial agent at which there is no visible 
growth, Figure 26. 
127 
 
      
 
       MIC 
 
 
Figure 26 Micro-dilution assay of N-(2-aminoethyl)-4-nitrobenzenesulfonamide 
trifluoroacetate 1d against PAO1 
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4.2.3 Results 
The six active compounds and the β-alanylciprofloxacin were tested against three different 
organisms; PAO1, B. subtilis, and P. vulgarus. The effect of the solvent was evaluated, 
Figure 27 and it is clear that there is no effect of acetone on the bacterial growth. The 
micro-dilution assay data highlighted that into three classes: 
 N-(2-Aminoethyl)-4-nitrobenzenesulfonamide trifluoroacetate 1d has the greatest 
effect against PAO1, with an MIC of 78.125 µg/ml, Figure 28. 
 N-(2-Aminoethyl)-4-nitrobenzenesulfonamide trifluoroacetate 1d also has the 
greatest effect against B. subtilis, with an MIC of 156.25 µg/ml, Figure 29. 
 Compounds N-(2-aminoethyl)-2-nitrophenylsulfonamide trifluoroacetate 1e, N-(2-
aminoethyl)-4-chlorophenylsulfonamide trifluoroacetate 1c, and N-(2-aminoethyl)-
4-nitrobenzenesulfonamide trifluoroacetate 1d have MIC of 156.25 µg/ml against P. 
vulgaris.Figure 30.  
A micro-dilution assay was also conducted in order to evaluate the effect of the coupling 
with β-alanyl on the selectivity of ciprofloxacin towards the previously mentioned strains, 
and the results demonstrate that there is no selectivity effect, but that the coupled 
ciprofloxacin has a greater effect than the other six compounds, Figure 31.     
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A 
 
B 
Figure 27 Effect on bacterial growth of PAO1 of 1d (A) and acetone solvent (B) 
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                     Figure 28 Micro-dilution assay in PAO1 at concentrations of 0-5000 µg/ml 
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                    Figure 29 Micro-dilution assay in B. subtili at concentrations of 0-5000 µg/ml 
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                     Figure 30 Micro-dilution assay in P. vulgaris at concentrations of 0-5000 µg/ml 
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                    Figure 31 Micro-dilution for ciprofloxacin and its β-alanyl analog 11 in PAO1, B. subtilis, and P. vulgaris 
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4.3 Cytotoxic effect of compounds on a human cell line  
The MTT assay is widely used to evaluate the in vitro cytotoxic activity of drugs on cell 
lines. MTT assay is a colorimetric assay based on conversion of the yellow MTT to purple 
formazan crystals by cellular reductase enzyme in living cells Scheme 9. Formazan is 
largely impermeable to the cell membrane, thus resulting in its aggregation within living 
cells. The number of surviving cells is directly correlated to the degree of the formazan 
generated, the color can then be quantified using a simple colorimetric assay.  
 
 
Scheme 9 Reaction scheme for the MTT assay 
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4.3.1 Preparation of MTT solution  
The MTT stock solution 12 mM was prepared by dissolving (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (Sigma Aldrich) in phosphate buffered saline (5 mg/mL, 
Sigma Aldrich) then filtering through a 0.2 µm syringe filter (Corning).  
 
4.3.2 Prostate cancer (PC3 cell line) assay 
PC3 cells were grown to ~70-80% confluence, seeded into 96-well plates at 3000 cells/well 
and incubated for 24 h. The seven previously identified active compounds were dissolved 
in DMSO and prepared as 200 mM stock solutions. The solutions were then diluted with 
RPMI 1640 media supplemented with 10 % foetal bovine serum and filtered through a 0.2 
µm syringe filter, then added into the 96-well plate. The final concentrations of the 
compounds were 100, 50 and 10 µM and each concentration was added to 6 wells. 0.1% of 
DMSO in media was also prepared and added to 6 wells of the plate, and this was used as a 
standard control for each plate. The plates were then incubated for a further 72 hours (T72). 
The medium was then removed from each well and was replaced with 10 % MTT stock 
solution in serum and phenol red-free medium (100 µL/ well). The plates were then 
incubated for 3 hours, the medium was then removed and replaced with DMSO (50 µL/ 
well). After mixing, the plates were placed in the microplate reader (FLUOstar Omega) and 
the absorbance was read at 540 nm. A control plate was prepared in the same way as above 
and read 24 hours (T0) after seeding; this was used as a control to give an indication of the 
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number of cells before drug treatment. The cell viability was then calculated as a 
percentage using the following formula:   
 
Viability =  
4.3.3 Preparation of HeKa (primary human keratinocytes-adult) 
cells 
The cells were purchased from Gibco Invitrogen and were cultured according to the 
manufacturer’s recommendations using a defined culture system. The assays were 
conducted using the same method as above, except that cells were seeded at 2000 
cells/well.  
4.3.4 Results from cytotoxicity tests 
The MTT assay on the prostate cancer (PC3) cell line shows that the all compounds have 
little effect on the growth of prostate cancer cell, except N-(2-aminoethyl)-4-
nitrobenzenesulfonamide trifluoroacetate 1d, which is highly cytotoxic at high 
concentration (100 µM), Figure 32. 
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Figure 32 Cell viability (MTT assay) for the active compounds in the PC3 cell line 
 
The viability assay on human keratinocytes cells line shows that only N-(2-aminoethyl)-4-
nitrobenzenesulfonamide trifluoroacetate 1d, results in the inhibition of growth at 50 µM 
and 100 µM, while the rest of the synthesized compounds have no effect, Figure 33. 
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Figure 33 Cell viability (MTT assay) for the active compounds in HeKa cells 
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5. Conclusions 
This project was based upon previous work on the synthesis of new chromogenic substrates 
for the identification of the Gram negative multi-drug resistant Pseudomonas aeruginosa, 
which suggested the presence of β-alanyl aminopeptidase in this bacterium. In this project, 
a 3-D model of β-alanyl aminopeptidase has been constructed and evaluated. Virtual 
database screening was then conducted in an attempt to discover novel inhibitors of this 
target enzyme. Twenty-seven novel compounds were synthesized, purified, and 
characterized and β-alanine was linked to these synthesized compounds. The 
fluoroquinolone antibiotic ciprofloxacin was also coupled to β–alanine and all compounds 
were evaluated for anti-pseudomonal activity.  
In disc diffusion assays, N-(2-aminoethyl)benzenesulfonamide trifluoroacetate salt 1a, N-
(2-aminoethyl)-4-methylbenzenesulfonamide trifluoroacetate salt 1b, N-(2-aminoethyl)-4-
chlorophenylsulfonamide trifluoroacetate 1c, N-(2-aminoethyl)-4-nitrophenylsulfonamide 
trifluoroacetate 1d, N-(2-aminoethyl)-2-nitrophenylsulfonamide trifluoroacetate 1e, and 3-
amino-N-{2-(2-nitrophenylsulfonamido)ethyl}propanamide trifluoroacetate 8e showed the 
greatest anti-pseudomonal activity, Table 13. 
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Table 13 Disc diffusion assay for the active compounds against PAO1 (at 100 mg/ml 
concentration)  
Compound  
ID 
Compound name Zone of 
inhibition (mm) 
1a N-(2-aminoethyl)benzenesulfonamide trifluoroacetate salt No growth on 
sterile disc 
1b N-(2-aminoethyl)-4-methylbenzenesulfonamide 
trifluoroacetate salt 
2 
1c N-(2-aminoethyl)-4-chlorophenylsulfonamide 
trifluoroacetate 
6 
1d N-(2-aminoethyl)-4-nitrophenylsulfonamide 
trifluoroacetate 
9 
1e N-(2-aminoethyl)-2-nitrophenylsulfonamide 
trifluoroacetate 
5.5 
8e 3-amino-N-{2-(2-
nitrophenylsulfonamido)ethyl}propanamide 
trifluoroacetate 
6.5 
 
N-(2-Aminoethyl)-4-nitrophenylsulfonamide trifluoroacetate 1d, 3-amino-N-{2-(2-
nitrophenylsulfonamido)ethyl}propanamide trifluoroacetate 8e, and N-(2-aminoethyl)-4-
chlorophenylsulfonamide trifluoroacetate 1c had the greatest anti-pseudomonal activity. In 
order to determine the selectivity of their antibacterial activity, the active compounds were 
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also tested against the Gram negative Proteus vulgaris and Gram positive Bacillus subtilise.  
3-Amino-N-{2-(2-nitrophenylsulfonamido)ethyl}propanamide trifluoroacetate 8e had the 
greatest selectivity, followed by N-(2-aminoethyl)-4-chlorophenylsulfonamide 
trifluoroacetate 1c and N-(2-aminoethyl)-4-methylbenzenesulfonamide trifluoroacetate salt 
1b, while N-(2-aminoethyl)-2-nitrophenylsulfonamide trifluoroacetate 1e and N-(2-
aminoethyl)-4-nitrophenylsulfonamide trifluoroacetate 1d had no selectivity, with strong 
inhibitory effects against all three bacterial species, Table 14. 
Table 14 Disc diffusion assay for the active compounds at 100 mg/ml concentration 
against PAO1, B. subtilis, and P. vulgaris 
Compound 
ID 
Zone diameter (mm) 
P. aeruginosa B. subtilis P. vulgaris 
8e 6.8 0.3 1.3 
1c 5.2 0.7 1.8 
1b 2 0 0 
1d 9 6.5 8.5 
1a Clear disc 0 0 
1e 5.5 4.5 4.5 
 
As shown in Table 14, the 3-amino-N-{2-(2-nitrophenylsulfonamido)ethyl}propanamide 
8e showed some selectivity, with a 6.8 mm zone of inhibition for PAO1 with only 0.3 and 
1.3 mm zones for B. subtilis and P. vulgaris respectively.  In addition, the N-(2-
aminoethyl)-4-chlorophenylsulfonamide 1c produced a zone of inhibition of 5.2 mm 
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against PAO1, and 0.7 and 1.8 mm zones for B. subtilis and P. vulgaris, respectively. In 
contrast, in a micro-dilution assay, compound 1d showed the greatest anti-pseudomonal 
effect, with an MIC of 78.125 µg/ml, although this effect was not specific as it also had the 
greatest effect against B. subtilis and P. vulgaris, with an MIC of 156.25 µg/ml for both 
species. 
In the micro-dilution assay, ciprofloxacin coupled to β-alanyl 11 showed greater effect than 
the other six compounds, with no selectivity against P. aeruginosa. An MTT assay using 
PC3 and HeKa cells showed that all compounds have little effect on the growth of the 
prostate cancer (PC3) and HeKa cells, except N-(2-aminoethyl)-4-nitrobenzenesulfonamide 
trifluoroacetate 1d which was cytotoxic to the  PC3 cell line at high concentration (100 
µM), and cytotoxic to HeKa cells at 50 µM and 100 µM. Although compounds 8e, 1c, and 
1b have selective effects upon PA01, their anti-pseudomonal activities are not sufficient for 
the development of potent anti-pseudomonal agents, suggesting that β-alanyl 
aminopeptidase has no physiological role in the growth of Pseudomonas aeruginosa. The 
results obtained in this work do, however, support further work to enhance the activity of 
these non-classical sulphonamides, as well as proteomics and protein purification in order 
to isolate and study β-alanyl aminopeptidase crystallographically. 
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